var title_f34_60_35776="Ofloxacin: Drug information";
var content_f34_60_35776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=see_link\">",
"       Ofloxacin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=see_link\">",
"       Ofloxacin (otic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=see_link\">",
"       Ofloxacin (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9715 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35776=[""].join("\n");
var outline_f34_60_35776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35777="AF activation patterns";
var content_f34_60_35777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Activation patterns in atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isochronal activation maps obtained from the right atrial free wall during atrial fibrillation show four distinct patterns of myocardial activation, indicated by black arrows. Activation from a localizable site which spreads in all directions away from the site is termed focal atrial activation (upper left). Type I activation is a single broad wavefront that propagates without conduction delay (upper right). Type II activation is a single wavefront that is associated with conduction slowing or block, or with two wavefronts (lower left). Type III activation results from the presence of three or more wave fronts associated with areas of slow and blocked conduction (lower right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Holm M, Johansson R, Brandt J, et al. Eur Heart J 1997; 18:290.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35777=[""].join("\n");
var outline_f34_60_35777=null;
var title_f34_60_35778="EUS liver metastasis FNA";
var content_f34_60_35778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of liver metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Endoscopic ultrasound (EUS) image of a&nbsp;2 cm left liver lesion. B) EUS-guided fine-needle aspiration (FNA) of the lesion. The radio-opaque needle can be seen entering the lesion from the upper right.&nbsp;C) Cytology showing non-small cell carcinoma&nbsp;(60X).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35778=[""].join("\n");
var outline_f34_60_35778=null;
var title_f34_60_35779="Olopatadine (nasal): Patient drug information";
var content_f34_60_35779=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olopatadine (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32404?source=see_link\">",
"     see \"Olopatadine (nasal): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9502825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Patanase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olopatadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12273 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35779=[""].join("\n");
var outline_f34_60_35779=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502825\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024463\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024462\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024467\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024468\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024470\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024465\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024466\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024471\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024472\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32404?source=related_link\">",
"      Olopatadine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/43/20147?source=related_link\">",
"      Olopatadine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8228?source=related_link\">",
"      Olopatadine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35780="Clotrimazole (oral): Drug information";
var content_f34_60_35780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clotrimazole (oral): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/44/5828?source=see_link\">",
"    see \"Clotrimazole (oral): Patient drug information \"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/6/15460?source=see_link\">",
"    see \"Clotrimazole (oral): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8011989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral Nonabsorbed",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8011693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Oropharyngeal candidiasis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     10 mg troche dissolved 3 times/day for the duration of chemotherapy or until steroids are reduced to maintenance levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     10 mg troche dissolved slowly 5 times/day for 14 consecutive days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8011692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/6/15460?source=see_link\">",
"      see \"Clotrimazole (oral): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Oropharyngeal candidiasis:",
"     </b>",
"     Children &gt;3 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8011694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8011732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Troche, oral: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8011647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8011696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Allow troche to dissolve slowly over 15-30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8011648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible fungal infections, including oropharyngeal candidiasis; limited data suggest that clotrimazole troches may be effective for prophylaxis against oropharyngeal candidiasis in neutropenic patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8011644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clotrimazole may be confused with co-trimoxazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mycelex may be confused with Myoflex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cloderm: Brand name for clotrimazole [Germany], but also brand name for alclomethasone [Indonesia]; clobetasol [China, India, Malaysia, Singapore, Thailand]; clocortolone [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Canesten [multiple international markets] may be confused with Canesten Bifonazol Comp brand name for bifonazole/urea [Austria]; Canesten Extra brand name for bifonazole [China, Germany]; Canesten Extra Nagelset brand name for bifonazole/urea [Denmark]; Canesten Fluconazole brand name for fluconazole [New Zealand]; Canesten Oasis brand name for sodium citrate [Great Britain]; Canesten Once Daily brand name for bifonazole [Australia]; Canesten Oral brand name for fluconazole [United Kingdom]; Cenestin brand name for estrogens (conjugated A/synthetic) [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mycelex: Brand name for clotrimazole [U.S.] may be confused with Mucolex brand name for bromhexine [Malaysia]; carbocisteine [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8011656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     &gt;10%: Hepatic: Abnormal liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8011652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clotrimazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8011653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic fungal infection: Clotrimazole should not be used for treatment of systemic fungal infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of clotrimazole lozenges (troches) have not been established in children &lt;3 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8011660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8011661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Clotrimazole (Oral) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8011650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, adverse events were observed with oral administration of clotrimazole.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8011651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8011734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Troche",
"     </b>",
"     (Clotrimazole Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (70): $112.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8011699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests during oral therapy with clotrimazole troche",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8011685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to phospholipids in the fungal cell membrane altering cell wall permeability resulting in loss of essential intracellular elements",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8011687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Oral (troche): Inhibitory concentrations remain in the saliva for up to 3 hours after dissolution of the troche",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Duhm B, Medenwald H, Puetter J, et al, &ldquo;The Pharmacokinetics of Clotrimazole 14C,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1974, 50(Suppl 1):13-6.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9071 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35780=[""].join("\n");
var outline_f34_60_35780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011989\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011693\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011692\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011694\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011732\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011647\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011696\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011648\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011656\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011652\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011653\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011660\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011661\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011650\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775509\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011651\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011734\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011699\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011685\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011687\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9071|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/44/5828?source=related_link\">",
"      Clotrimazole (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/6/15460?source=related_link\">",
"      Clotrimazole (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/61/29652?source=related_link\">",
"      Clotrimazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41556?source=related_link\">",
"      Clotrimazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/28/13763?source=related_link\">",
"      Clotrimazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35781="Ibuprofen and famotidine: Patient drug information";
var content_f34_60_35781=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ibuprofen and famotidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23096?source=see_link\">",
"     see \"Ibuprofen and famotidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12993070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Duexis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12808789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12808791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop NSAID-associated gastric ulcers in patients with a history of ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12808790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3435900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ibuprofen, famotidine, aspirin, NSAIDs, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 30 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12808795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12808796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12808798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12808793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12808794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12808799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12808800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16489 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-BE3A184D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35781=[""].join("\n");
var outline_f34_60_35781=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12993070\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808789\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808791\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808790\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808795\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808796\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808798\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808793\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808794\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808799\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808800\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23096?source=related_link\">",
"      Ibuprofen and famotidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35782="Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)";
var content_f34_60_35782=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodyMassIndexGirls_form\" name=\"BodyMassIndexGirls_form\" onkeydown=\"clrResults();\" onkeyup=\"BodyMassIndexGirls_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          BMI = Weight / (Height/100)",
"          <sup>",
"           2",
"          </sup>",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"BodyMassIndexGirls_fx(); minMaxCheck();\" onchange=\"BodyMassIndexGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"BodyMassIndexGirls_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"BodyMassIndexGirls_fx(); minMaxCheck();\" onchange=\"BodyMassIndexGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BodyMassIndexGirls_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"BodyMassIndexGirls_fx(); minMaxCheck();\" onchange=\"BodyMassIndexGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BodyMassIndexGirls_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              BMI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"BMI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                kg/m",
"                <sup>",
"                 2",
"                </sup>",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Z Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"BodyMassIndexGirls_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         BMI Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt; 5:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Underweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 5 and &lt; 85:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Healthy weight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 85 and &lt; 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Overweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Obesity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      At the extremes (&gt; 97th percentile or &lt; 3rd percentile), small differences in percentiles represent  clinically important differences in BMI. At these extremes, the z-score is a more precise reflection  of how far the measurement deviates from the mean, and is a useful tool for tracking changes.",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Examples",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"3\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"40%\">",
"       <tr>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Z-score",
"         </b>",
"        </td>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Percentile equivalent",
"         </b>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 1.0",
"        </td>",
"        <td align=\"center\">",
"         84",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 2.0",
"        </td>",
"        <td align=\"center\">",
"         97.5",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 2.5",
"        </td>",
"        <td align=\"center\">",
"         99.4",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 3.0",
"        </td>",
"        <td align=\"center\">",
"         99.7",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Girls: BMI for Age. National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35782=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.BodyMassIndexGirls_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodyMassIndexGirls_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BodyMassIndexGirls_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Age_Months =  Age * 12;",
"",
"if(Age_Months >= 24 && Age_Months < 25){L = -1.024496827; M = 16.38804056; S = 0.085025838;};",
"if(Age_Months >= 25 && Age_Months < 26){L = -1.102698353; M = 16.3189719; S = 0.084214052;};",
"if(Age_Months >= 26 && Age_Months < 27){L = -1.18396635; M = 16.25207985; S = 0.083455124;};",
"if(Age_Months >= 27 && Age_Months < 28){L = -1.268071036; M = 16.18734669; S = 0.082748284;};",
"if(Age_Months >= 28 && Age_Months < 29){L = -1.354751525; M = 16.12475448; S = 0.082092737;};",
"if(Age_Months >= 29 && Age_Months < 30){L = -1.443689692; M = 16.06428762; S = 0.081487717;};",
"if(Age_Months >= 30 && Age_Months < 31){L = -1.53454192; M = 16.00593001; S = 0.080932448;};",
"if(Age_Months >= 31 && Age_Months < 32){L = -1.626928093; M = 15.94966631; S = 0.080426175;};",
"if(Age_Months >= 32 && Age_Months < 33){L = -1.720434829; M = 15.89548197; S = 0.079968176;};",
"if(Age_Months >= 33 && Age_Months < 34){L = -1.814635262; M = 15.84336179; S = 0.079557735;};",
"if(Age_Months >= 34 && Age_Months < 35){L = -1.909076262; M = 15.79329146; S = 0.079194187;};",
"if(Age_Months >= 35 && Age_Months < 36){L = -2.003296102; M = 15.7452564; S = 0.078876895;};",
"if(Age_Months >= 36 && Age_Months < 37){L = -2.096828937; M = 15.69924188; S = 0.078605255;};",
"if(Age_Months >= 37 && Age_Months < 38){L = -2.189211877; M = 15.65523282; S = 0.078378696;};",
"if(Age_Months >= 38 && Age_Months < 39){L = -2.279991982; M = 15.61321371; S = 0.078196674;};",
"if(Age_Months >= 39 && Age_Months < 40){L = -2.368732949; M = 15.57316843; S = 0.078058667;};",
"if(Age_Months >= 40 && Age_Months < 41){L = -2.455021314; M = 15.53508019; S = 0.077964169;};",
"if(Age_Months >= 41 && Age_Months < 42){L = -2.538471972; M = 15.49893145; S = 0.077912684;};",
"if(Age_Months >= 42 && Age_Months < 43){L = -2.618732901; M = 15.46470384; S = 0.077903716;};",
"if(Age_Months >= 43 && Age_Months < 44){L = -2.695488973; M = 15.43237817; S = 0.077936763;};",
"if(Age_Months >= 44 && Age_Months < 45){L = -2.768464816; M = 15.40193436; S = 0.078011309;};",
"if(Age_Months >= 45 && Age_Months < 46){L = -2.837426693; M = 15.37335154; S = 0.078126817;};",
"if(Age_Months >= 46 && Age_Months < 47){L = -2.902178205; M = 15.34660842; S = 0.078282739;};",
"if(Age_Months >= 47 && Age_Months < 48){L = -2.962580386; M = 15.32168181; S = 0.078478449;};",
"if(Age_Months >= 48 && Age_Months < 49){L = -3.018521987; M = 15.29854897; S = 0.078713325;};",
"if(Age_Months >= 49 && Age_Months < 50){L = -3.069936555; M = 15.27718618; S = 0.078986694;};",
"if(Age_Months >= 50 && Age_Months < 51){L = -3.116795864; M = 15.2575692; S = 0.079297841;};",
"if(Age_Months >= 51 && Age_Months < 52){L = -3.159107331; M = 15.23967338; S = 0.079646006;};",
"if(Age_Months >= 52 && Age_Months < 53){L = -3.196911083; M = 15.22347371; S = 0.080030389;};",
"if(Age_Months >= 53 && Age_Months < 54){L = -3.230276759; M = 15.20894491; S = 0.080450145;};",
"if(Age_Months >= 54 && Age_Months < 55){L = -3.259300182; M = 15.19606152; S = 0.080904391;};",
"if(Age_Months >= 55 && Age_Months < 56){L = -3.284099963; M = 15.18479799; S = 0.081392203;};",
"if(Age_Months >= 56 && Age_Months < 57){L = -3.30481415; M = 15.17512871; S = 0.081912623;};",
"if(Age_Months >= 57 && Age_Months < 58){L = -3.321596954; M = 15.16702811; S = 0.082464661;};",
"if(Age_Months >= 58 && Age_Months < 59){L = -3.334615646; M = 15.16047068; S = 0.083047295;};",
"if(Age_Months >= 59 && Age_Months < 60){L = -3.344047622; M = 15.15543107; S = 0.083659478;};",
"if(Age_Months >= 60 && Age_Months < 61){L = -3.35007771; M = 15.15188405; S = 0.084300139;};",
"if(Age_Months >= 61 && Age_Months < 62){L = -3.352893805; M = 15.14980479; S = 0.0849682;};",
"if(Age_Months >= 62 && Age_Months < 63){L = -3.352691376; M = 15.14916825; S = 0.085662539;};",
"if(Age_Months >= 63 && Age_Months < 64){L = -3.34966438; M = 15.14994984; S = 0.086382035;};",
"if(Age_Months >= 64 && Age_Months < 65){L = -3.343998803; M = 15.15212585; S = 0.087125591;};",
"if(Age_Months >= 65 && Age_Months < 66){L = -3.335889574; M = 15.15567186; S = 0.087892047;};",
"if(Age_Months >= 66 && Age_Months < 67){L = -3.325522491; M = 15.16056419; S = 0.088680264;};",
"if(Age_Months >= 67 && Age_Months < 68){L = -3.31307846; M = 15.16677947; S = 0.089489106;};",
"if(Age_Months >= 68 && Age_Months < 69){L = -3.298732648; M = 15.17429464; S = 0.090317434;};",
"if(Age_Months >= 69 && Age_Months < 70){L = -3.282653831; M = 15.18308694; S = 0.091164117;};",
"if(Age_Months >= 70 && Age_Months < 71){L = -3.265003896; M = 15.1931339; S = 0.092028028;};",
"if(Age_Months >= 71 && Age_Months < 72){L = -3.245937506; M = 15.20441335; S = 0.092908048;};",
"if(Age_Months >= 72 && Age_Months < 73){L = -3.225606516; M = 15.21690296; S = 0.093803033;};",
"if(Age_Months >= 73 && Age_Months < 74){L = -3.204146115; M = 15.2305815; S = 0.094711916;};",
"if(Age_Months >= 74 && Age_Months < 75){L = -3.181690237; M = 15.24542745; S = 0.095633595;};",
"if(Age_Months >= 75 && Age_Months < 76){L = -3.158363475; M = 15.26141966; S = 0.096566992;};",
"if(Age_Months >= 76 && Age_Months < 77){L = -3.134282833; M = 15.27853728; S = 0.097511046;};",
"if(Age_Months >= 77 && Age_Months < 78){L = -3.109557879; M = 15.29675967; S = 0.09846471;};",
"if(Age_Months >= 78 && Age_Months < 79){L = -3.084290931; M = 15.31606644; S = 0.099426955;};",
"if(Age_Months >= 79 && Age_Months < 80){L = -3.058577292; M = 15.33643745; S = 0.100396769;};",
"if(Age_Months >= 80 && Age_Months < 81){L = -3.032505499; M = 15.35785274; S = 0.101373159;};",
"if(Age_Months >= 81 && Age_Months < 82){L = -3.0061576; M = 15.38029261; S = 0.10235515;};",
"if(Age_Months >= 82 && Age_Months < 83){L = -2.979609448; M = 15.40373754; S = 0.103341788;};",
"if(Age_Months >= 83 && Age_Months < 84){L = -2.952930993; M = 15.42816819; S = 0.104332139;};",
"if(Age_Months >= 84 && Age_Months < 85){L = -2.926186592; M = 15.45356545; S = 0.105325289;};",
"if(Age_Months >= 85 && Age_Months < 86){L = -2.899435307; M = 15.47991037; S = 0.106320346;};",
"if(Age_Months >= 86 && Age_Months < 87){L = -2.872731211; M = 15.50718419; S = 0.10731644;};",
"if(Age_Months >= 87 && Age_Months < 88){L = -2.846123683; M = 15.53536829; S = 0.108312721;};",
"if(Age_Months >= 88 && Age_Months < 89){L = -2.819657704; M = 15.56444426; S = 0.109308364;};",
"if(Age_Months >= 89 && Age_Months < 90){L = -2.793374145; M = 15.5943938; S = 0.110302563;};",
"if(Age_Months >= 90 && Age_Months < 91){L = -2.767310047; M = 15.6251988; S = 0.111294537;};",
"if(Age_Months >= 91 && Age_Months < 92){L = -2.741498897; M = 15.65684126; S = 0.112283526;};",
"if(Age_Months >= 92 && Age_Months < 93){L = -2.715970894; M = 15.68930333; S = 0.113268793;};",
"if(Age_Months >= 93 && Age_Months < 94){L = -2.690753197; M = 15.7225673; S = 0.114249622;};",
"if(Age_Months >= 94 && Age_Months < 95){L = -2.665870146; M = 15.75661555; S = 0.115225321;};",
"if(Age_Months >= 95 && Age_Months < 96){L = -2.641343436; M = 15.79143062; S = 0.116195218;};",
"if(Age_Months >= 96 && Age_Months < 97){L = -2.617192204; M = 15.82699517; S = 0.117158667;};",
"if(Age_Months >= 97 && Age_Months < 98){L = -2.593430614; M = 15.86329241; S = 0.118115073;};",
"if(Age_Months >= 98 && Age_Months < 99){L = -2.570076037; M = 15.90030484; S = 0.119063807;};",
"if(Age_Months >= 99 && Age_Months < 100){L = -2.547141473; M = 15.93801545; S = 0.12000429;};",
"if(Age_Months >= 100 && Age_Months < 101){L = -2.524635245; M = 15.97640787; S = 0.120935994;};",
"if(Age_Months >= 101 && Age_Months < 102){L = -2.502569666; M = 16.01546483; S = 0.121858355;};",
"if(Age_Months >= 102 && Age_Months < 103){L = -2.48095189; M = 16.05516984; S = 0.12277087;};",
"if(Age_Months >= 103 && Age_Months < 104){L = -2.459785573; M = 16.09550688; S = 0.123673085;};",
"if(Age_Months >= 104 && Age_Months < 105){L = -2.439080117; M = 16.13645881; S = 0.124564484;};",
"if(Age_Months >= 105 && Age_Months < 106){L = -2.418838304; M = 16.17800955; S = 0.125444639;};",
"if(Age_Months >= 106 && Age_Months < 107){L = -2.399063683; M = 16.22014281; S = 0.126313121;};",
"if(Age_Months >= 107 && Age_Months < 108){L = -2.379756861; M = 16.26284277; S = 0.127169545;};",
"if(Age_Months >= 108 && Age_Months < 109){L = -2.360920527; M = 16.30609316; S = 0.128013515;};",
"if(Age_Months >= 109 && Age_Months < 110){L = -2.342557728; M = 16.34987759; S = 0.128844639;};",
"if(Age_Months >= 110 && Age_Months < 111){L = -2.324663326; M = 16.39418118; S = 0.129662637;};",
"if(Age_Months >= 111 && Age_Months < 112){L = -2.307240716; M = 16.43898741; S = 0.130467138;};",
"if(Age_Months >= 112 && Age_Months < 113){L = -2.290287663; M = 16.48428082; S = 0.131257852;};",
"if(Age_Months >= 113 && Age_Months < 114){L = -2.273803847; M = 16.53004554; S = 0.132034479;};",
"if(Age_Months >= 114 && Age_Months < 115){L = -2.257782149; M = 16.57626713; S = 0.132796819;};",
"if(Age_Months >= 115 && Age_Months < 116){L = -2.242227723; M = 16.62292864; S = 0.133544525;};",
"if(Age_Months >= 116 && Age_Months < 117){L = -2.227132805; M = 16.67001572; S = 0.134277436;};",
"if(Age_Months >= 117 && Age_Months < 118){L = -2.212495585; M = 16.71751288; S = 0.134995324;};",
"if(Age_Months >= 118 && Age_Months < 119){L = -2.19831275; M = 16.76540496; S = 0.135697996;};",
"if(Age_Months >= 119 && Age_Months < 120){L = -2.184580762; M = 16.81367689; S = 0.136385276;};",
"if(Age_Months >= 120 && Age_Months < 121){L = -2.171295888; M = 16.86231366; S = 0.137057004;};",
"if(Age_Months >= 121 && Age_Months < 122){L = -2.158454232; M = 16.91130036; S = 0.137713039;};",
"if(Age_Months >= 122 && Age_Months < 123){L = -2.146051754; M = 16.96062216; S = 0.138353254;};",
"if(Age_Months >= 123 && Age_Months < 124){L = -2.134084303; M = 17.0102643; S = 0.138977537;};",
"if(Age_Months >= 124 && Age_Months < 125){L = -2.122547629; M = 17.06021213; S = 0.139585795;};",
"if(Age_Months >= 125 && Age_Months < 126){L = -2.111437411; M = 17.11045106; S = 0.140177947;};",
"if(Age_Months >= 126 && Age_Months < 127){L = -2.100749266; M = 17.16096656; S = 0.140753927;};",
"if(Age_Months >= 127 && Age_Months < 128){L = -2.090478774; M = 17.21174424; S = 0.141313686;};",
"if(Age_Months >= 128 && Age_Months < 129){L = -2.080621484; M = 17.26276973; S = 0.141857186;};",
"if(Age_Months >= 129 && Age_Months < 130){L = -2.071172932; M = 17.31402878; S = 0.142384404;};",
"if(Age_Months >= 130 && Age_Months < 131){L = -2.062128649; M = 17.3655072; S = 0.142895332;};",
"if(Age_Months >= 131 && Age_Months < 132){L = -2.053484173; M = 17.4171909; S = 0.143389972;};",
"if(Age_Months >= 132 && Age_Months < 133){L = -2.045235058; M = 17.46906585; S = 0.143868341;};",
"if(Age_Months >= 133 && Age_Months < 134){L = -2.03737688; M = 17.52111811; S = 0.144330469;};",
"if(Age_Months >= 134 && Age_Months < 135){L = -2.029906684; M = 17.57333347; S = 0.144776372;};",
"if(Age_Months >= 135 && Age_Months < 136){L = -2.022817914; M = 17.62569869; S = 0.145206138;};",
"if(Age_Months >= 136 && Age_Months < 137){L = -2.016107084; M = 17.67819987; S = 0.145619819;};",
"if(Age_Months >= 137 && Age_Months < 138){L = -2.009769905; M = 17.7308234; S = 0.146017491;};",
"if(Age_Months >= 138 && Age_Months < 139){L = -2.003802134; M = 17.78355575; S = 0.146399239;};",
"if(Age_Months >= 139 && Age_Months < 140){L = -1.998199572; M = 17.83638347; S = 0.146765161;};",
"if(Age_Months >= 140 && Age_Months < 141){L = -1.992958064; M = 17.88929321; S = 0.147115364;};",
"if(Age_Months >= 141 && Age_Months < 142){L = -1.988073505; M = 17.94227168; S = 0.147449967;};",
"if(Age_Months >= 142 && Age_Months < 143){L = -1.983541835; M = 17.9953057; S = 0.147769097;};",
"if(Age_Months >= 143 && Age_Months < 144){L = -1.979359041; M = 18.04838216; S = 0.148072891;};",
"if(Age_Months >= 144 && Age_Months < 145){L = -1.975521156; M = 18.10148804; S = 0.148361495;};",
"if(Age_Months >= 145 && Age_Months < 146){L = -1.972024258; M = 18.15461039; S = 0.148635067;};",
"if(Age_Months >= 146 && Age_Months < 147){L = -1.968864465; M = 18.20773639; S = 0.148893769;};",
"if(Age_Months >= 147 && Age_Months < 148){L = -1.966037938; M = 18.26085325; S = 0.149137776;};",
"if(Age_Months >= 148 && Age_Months < 149){L = -1.963540872; M = 18.31394832; S = 0.14936727;};",
"if(Age_Months >= 149 && Age_Months < 150){L = -1.961369499; M = 18.36700902; S = 0.149582439;};",
"if(Age_Months >= 150 && Age_Months < 151){L = -1.959520079; M = 18.42002284; S = 0.149783482;};",
"if(Age_Months >= 151 && Age_Months < 152){L = -1.9579889; M = 18.47297739; S = 0.149970604;};",
"if(Age_Months >= 152 && Age_Months < 153){L = -1.956772271; M = 18.52586035; S = 0.15014402;};",
"if(Age_Months >= 153 && Age_Months < 154){L = -1.95586652; M = 18.57865951; S = 0.15030395;};",
"if(Age_Months >= 154 && Age_Months < 155){L = -1.955267984; M = 18.63136275; S = 0.150450621;};",
"if(Age_Months >= 155 && Age_Months < 156){L = -1.954973011; M = 18.68395801; S = 0.15058427;};",
"if(Age_Months >= 156 && Age_Months < 157){L = -1.954977947; M = 18.73643338; S = 0.150705138;};",
"if(Age_Months >= 157 && Age_Months < 158){L = -1.955279136; M = 18.788777; S = 0.150813475;};",
"if(Age_Months >= 158 && Age_Months < 159){L = -1.955872909; M = 18.84097713; S = 0.150909535;};",
"if(Age_Months >= 159 && Age_Months < 160){L = -1.956755579; M = 18.89302212; S = 0.150993582;};",
"if(Age_Months >= 160 && Age_Months < 161){L = -1.957923436; M = 18.94490041; S = 0.151065883;};",
"if(Age_Months >= 161 && Age_Months < 162){L = -1.959372737; M = 18.99660055; S = 0.151126714;};",
"if(Age_Months >= 162 && Age_Months < 163){L = -1.9610997; M = 19.04811118; S = 0.151176355;};",
"if(Age_Months >= 163 && Age_Months < 164){L = -1.963100496; M = 19.09942105; S = 0.151215094;};",
"if(Age_Months >= 164 && Age_Months < 165){L = -1.96537124; M = 19.15051899; S = 0.151243223;};",
"if(Age_Months >= 165 && Age_Months < 166){L = -1.967907983; M = 19.20139397; S = 0.151261042;};",
"if(Age_Months >= 166 && Age_Months < 167){L = -1.970706706; M = 19.25203503; S = 0.151268855;};",
"if(Age_Months >= 167 && Age_Months < 168){L = -1.973763307; M = 19.30243131; S = 0.151266974;};",
"if(Age_Months >= 168 && Age_Months < 169){L = -1.977073595; M = 19.35257209; S = 0.151255713;};",
"if(Age_Months >= 169 && Age_Months < 170){L = -1.980633277; M = 19.40244671; S = 0.151235395;};",
"if(Age_Months >= 170 && Age_Months < 171){L = -1.984437954; M = 19.45204465; S = 0.151206347;};",
"if(Age_Months >= 171 && Age_Months < 172){L = -1.988483106; M = 19.50135548; S = 0.151168902;};",
"if(Age_Months >= 172 && Age_Months < 173){L = -1.992764085; M = 19.55036888; S = 0.151123398;};",
"if(Age_Months >= 173 && Age_Months < 174){L = -1.997276103; M = 19.59907464; S = 0.15107018;};",
"if(Age_Months >= 174 && Age_Months < 175){L = -2.002014224; M = 19.64746266; S = 0.151009595;};",
"if(Age_Months >= 175 && Age_Months < 176){L = -2.00697335; M = 19.69552294; S = 0.150942;};",
"if(Age_Months >= 176 && Age_Months < 177){L = -2.012148213; M = 19.7432456; S = 0.150867753;};",
"if(Age_Months >= 177 && Age_Months < 178){L = -2.017533363; M = 19.79062086; S = 0.150787221;};",
"if(Age_Months >= 178 && Age_Months < 179){L = -2.023123159; M = 19.83763907; S = 0.150700774;};",
"if(Age_Months >= 179 && Age_Months < 180){L = -2.028911755; M = 19.88429066; S = 0.150608788;};",
"if(Age_Months >= 180 && Age_Months < 181){L = -2.034893091; M = 19.9305662; S = 0.150511645;};",
"if(Age_Months >= 181 && Age_Months < 182){L = -2.041060881; M = 19.97645636; S = 0.150409731;};",
"if(Age_Months >= 182 && Age_Months < 183){L = -2.047408604; M = 20.02195192; S = 0.15030344;};",
"if(Age_Months >= 183 && Age_Months < 184){L = -2.05392949; M = 20.06704377; S = 0.150193169;};",
"if(Age_Months >= 184 && Age_Months < 185){L = -2.060616513; M = 20.11172291; S = 0.150079322;};",
"if(Age_Months >= 185 && Age_Months < 186){L = -2.067462375; M = 20.15598047; S = 0.149962308;};",
"if(Age_Months >= 186 && Age_Months < 187){L = -2.074459502; M = 20.19980767; S = 0.14984254;};",
"if(Age_Months >= 187 && Age_Months < 188){L = -2.081600029; M = 20.24319586; S = 0.149720441;};",
"if(Age_Months >= 188 && Age_Months < 189){L = -2.088875793; M = 20.28613648; S = 0.149596434;};",
"if(Age_Months >= 189 && Age_Months < 190){L = -2.096278323; M = 20.32862109; S = 0.149470953;};",
"if(Age_Months >= 190 && Age_Months < 191){L = -2.103798828; M = 20.37064138; S = 0.149344433;};",
"if(Age_Months >= 191 && Age_Months < 192){L = -2.111428194; M = 20.41218911; S = 0.149217319;};",
"if(Age_Months >= 192 && Age_Months < 193){L = -2.119156972; M = 20.45325617; S = 0.14909006;};",
"if(Age_Months >= 193 && Age_Months < 194){L = -2.126975375; M = 20.49383457; S = 0.14896311;};",
"if(Age_Months >= 194 && Age_Months < 195){L = -2.134873266; M = 20.5339164; S = 0.148836931;};",
"if(Age_Months >= 195 && Age_Months < 196){L = -2.142840157; M = 20.57349387; S = 0.148711989;};",
"if(Age_Months >= 196 && Age_Months < 197){L = -2.150865204; M = 20.61255929; S = 0.148588757;};",
"if(Age_Months >= 197 && Age_Months < 198){L = -2.158937201; M = 20.65110506; S = 0.148467715;};",
"if(Age_Months >= 198 && Age_Months < 199){L = -2.167044578; M = 20.6891237; S = 0.148349348;};",
"if(Age_Months >= 199 && Age_Months < 200){L = -2.175176987; M = 20.72660728; S = 0.14823412;};",
"if(Age_Months >= 200 && Age_Months < 201){L = -2.183317362; M = 20.76355011; S = 0.148122614;};",
"if(Age_Months >= 201 && Age_Months < 202){L = -2.191457792; M = 20.79994337; S = 0.148015249;};",
"if(Age_Months >= 202 && Age_Months < 203){L = -2.199583649; M = 20.83578051; S = 0.147912564;};",
"if(Age_Months >= 203 && Age_Months < 204){L = -2.207681525; M = 20.87105449; S = 0.147815078;};",
"if(Age_Months >= 204 && Age_Months < 205){L = -2.215737645; M = 20.90575839; S = 0.147723315;};",
"if(Age_Months >= 205 && Age_Months < 206){L = -2.223739902; M = 20.93988477; S = 0.147637768;};",
"if(Age_Months >= 206 && Age_Months < 207){L = -2.231667995; M = 20.97342858; S = 0.147559083;};",
"if(Age_Months >= 207 && Age_Months < 208){L = -2.239511942; M = 21.00638171; S = 0.147487716;};",
"if(Age_Months >= 208 && Age_Months < 209){L = -2.247257081; M = 21.0387374; S = 0.14742421;};",
"if(Age_Months >= 209 && Age_Months < 210){L = -2.254885145; M = 21.07048996; S = 0.147369174;};",
"if(Age_Months >= 210 && Age_Months < 211){L = -2.26238209; M = 21.10163241; S = 0.147323144;};",
"if(Age_Months >= 211 && Age_Months < 212){L = -2.269731517; M = 21.13215845; S = 0.147286698;};",
"if(Age_Months >= 212 && Age_Months < 213){L = -2.276917229; M = 21.16206171; S = 0.147260415;};",
"if(Age_Months >= 213 && Age_Months < 214){L = -2.283925442; M = 21.1913351; S = 0.147244828;};",
"if(Age_Months >= 214 && Age_Months < 215){L = -2.290731442; M = 21.21997472; S = 0.147240683;};",
"if(Age_Months >= 215 && Age_Months < 216){L = -2.29732427; M = 21.24797262; S = 0.147248467;};",
"if(Age_Months >= 216 && Age_Months < 217){L = -2.303687802; M = 21.27532239; S = 0.14726877;};",
"if(Age_Months >= 217 && Age_Months < 218){L = -2.309799971; M = 21.30201933; S = 0.147302299;};",
"if(Age_Months >= 218 && Age_Months < 219){L = -2.315651874; M = 21.32805489; S = 0.147349514;};",
"if(Age_Months >= 219 && Age_Months < 220){L = -2.32121731; M = 21.35342563; S = 0.147411215;};",
"if(Age_Months >= 220 && Age_Months < 221){L = -2.326481911; M = 21.37812462; S = 0.147487979;};",
"if(Age_Months >= 221 && Age_Months < 222){L = -2.331428139; M = 21.40214589; S = 0.147580453;};",
"if(Age_Months >= 222 && Age_Months < 223){L = -2.336038473; M = 21.42548351; S = 0.147689289;};",
"if(Age_Months >= 223 && Age_Months < 224){L = -2.34029545; M = 21.44813156; S = 0.14781515;};",
"if(Age_Months >= 224 && Age_Months < 225){L = -2.344181703; M = 21.47008412; S = 0.147958706;};",
"if(Age_Months >= 225 && Age_Months < 226){L = -2.34768; M = 21.49133529; S = 0.148120633;};",
"if(Age_Months >= 226 && Age_Months < 227){L = -2.350773286; M = 21.51187918; S = 0.148301619;};",
"if(Age_Months >= 227 && Age_Months < 228){L = -2.353444725; M = 21.53170989; S = 0.148502355;};",
"if(Age_Months >= 228 && Age_Months < 229){L = -2.355677743; M = 21.55082155; S = 0.148723546;};",
"if(Age_Months >= 229 && Age_Months < 230){L = -2.35745607; M = 21.56920824; S = 0.148965902;};",
"if(Age_Months >= 230 && Age_Months < 231){L = -2.358763788; M = 21.58686406; S = 0.149230142;};",
"if(Age_Months >= 231 && Age_Months < 232){L = -2.359585369; M = 21.60378309; S = 0.149516994;};",
"if(Age_Months >= 232 && Age_Months < 233){L = -2.359905726; M = 21.61995939; S = 0.149827195;};",
"if(Age_Months >= 233 && Age_Months < 234){L = -2.359710258; M = 21.635387; S = 0.150161492;};",
"if(Age_Months >= 234 && Age_Months < 235){L = -2.358980464; M = 21.65006126; S = 0.150520734;};",
"if(Age_Months >= 235 && Age_Months < 236){L = -2.357714508; M = 21.6639727; S = 0.150905439;};",
"if(Age_Months >= 236 && Age_Months < 237){L = -2.355892424; M = 21.67711736; S = 0.151316531;};",
"if(Age_Months >= 237 && Age_Months < 238){L = -2.353501353; M = 21.68948935; S = 0.151754808;};",
"if(Age_Months >= 238 && Age_Months < 239){L = -2.350528726; M = 21.70108288; S = 0.152221086;};",
"if(Age_Months >= 239 && Age_Months < 240){L = -2.346962247; M = 21.71189225; S = 0.152716206;};",
"if(Age_Months >= 240 && Age_Months < 241){L = -2.342796948; M = 21.72190973; S = 0.153240872;};",
"BMI =  Weight / power((Height / 100), 2);",
"",
"if (doCalc) BMI_param.value = fixDP(BMI, dp);",
"",
"",
"",
"Z_Score =  (power((BMI / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Percentile < 5){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Percentile >= 5) && (Percentile < 85)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Percentile >= 85) && (Percentile < 95)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (Percentile >= 95){ document.getElementById('rr1_4').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexGirls_form){",
"",
"if (Age_param.value && Age < 2) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 2 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 19.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 19.99 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height < 50) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 50 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 300) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 300 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight < 5) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 5 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 300) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 300 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexGirls_form){",
"",
"BMI_param.value = '';",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f34_60_35782=null;
var title_f34_60_35783="Neonatal epileptic syndromes";
var content_f34_60_35783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal epileptic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Eli M Mizrahi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35783/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/60/35783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the etiology of seizures is a primary clinical objective in the management of neonatal seizures. Accurate determination of the cause can lead to etiology-specific therapy and may limit central nervous system (CNS) dysfunction that would otherwise occur if left untreated. In addition, etiology-specific therapy may be necessary to control the seizures themselves.",
"   </p>",
"   <p>",
"    While there has been much discussion of the potential adverse effect of seizures on the immature brain, the overriding factor that affects long-term outcome is the etiology of the seizures and the degree and distribution of brain injury caused by the underlying disturbance.",
"   </p>",
"   <p>",
"    This topic review will discuss recognized neonatal epileptic syndromes. Acute reactive neonatal seizures are much more common than the neonatal epileptic syndromes and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=see_link\">",
"     \"Etiology and prognosis of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characterization of various types of neonatal seizures, with an emphasis upon clinical features and electrodiagnosis, is discussed elsewhere. Treatment is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most neonatal seizures can be categorized as \"symptomatic\" seizures and are representative of a group of disorders with identifiable etiologies (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"UTD.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ). The seizures are considered acute and reactive, with prognosis varying according to specific etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=see_link\">",
"     \"Etiology and prognosis of neonatal seizures\"",
"    </a>",
"    .) However, despite a complete evaluation for etiology, there will be some seizures that occur in the absence of any identifiable cause. When associated with other clinical signs that suggest central nervous system injury, their etiology may be considered \"cryptogenic.\" When such seizures occur in otherwise normal infants, the seizures are considered \"idiopathic.\"",
"   </p>",
"   <p>",
"    Although the majority of neonatal seizures occur as acute reactive events in response to identifiable etiologic factors, additional rare but distinct neonatal epileptic syndromes are well recognized. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign neonatal convulsions",
"     </li>",
"     <li>",
"      Benign neonatal familial convulsions",
"     </li>",
"     <li>",
"      Early myoclonic encephalopathy",
"     </li>",
"     <li>",
"      Early infantile epileptic encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The International League Against Epilepsy (ILAE) has classified these epileptic syndromes with the purposes of standardizing terminology and developing a more uniform understanding of the clinical features and consequences of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the ILAE scheme, the syndromes are characterized by a cluster of clinical signs, symptoms, and laboratory findings that include seizure type, age of onset, etiology, precipitating factors, severity, ictal and interictal EEG findings, duration of the disorder, associated clinical features, chronicity, response to antiepileptic drug (AED) therapy, and prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE REACTIVE SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is worth emphasizing again that almost all neonatal seizures are thought to be symptomatic (ie, acute and reactive), occurring as a consequence of a specific etiology (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"UTD.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/5\">",
"     5",
"    </a>",
"    ]. Seizures associated with the four ILAE designated syndromes are relatively rare. Acute reactive neonatal seizures are much more common than the neonatal epileptic syndromes and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=see_link\">",
"     \"Etiology and prognosis of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BENIGN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the neonatal seizure syndromes previously recognized by the ILAE are considered benign, as their name implies, and are associated with a relatively good prognosis: benign neonatal convulsions and benign familial neonatal convulsions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Benign neonatal convulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal convulsions is an idiopathic neonatal seizure syndrome. There are a number of terms that have been used to designate benign neonatal convulsions, including \"benign idiopathic neonatal convulsions\" and \"fifth day fits\" (because of their peak day of onset). No studies clearly link the diagnosis to a specific etiology, although two hypotheses have been investigated: acute zinc deficiency in cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/6\">",
"     6",
"    </a>",
"    ] and rotavirus in stool of affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the findings of these studies have not been confirmed. Even in the absence of a family history, some cases may be genetically based due to a de novo mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of benign neonatal convulsions varies widely, although most studies suggest they comprise 2 to 7 percent of neonatal seizures. The incidence has declined since it was first described in the early 1980s. The 2005-2009 ILAE commission proposed that the category of benign neonatal convulsions be eliminated because of its diminished occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seizures occur within the first seven days of life, with 90 percent occurring between days four and six. They occur in term or late preterm infants after an uneventful pregnancy, labor and delivery, with no family history of seizures, and with normal neurologic examinations between seizures.",
"   </p>",
"   <p>",
"    The most frequent seizure type is unifocal clonic, and associated apnea has sometimes been reported. Rarely, the seizures have been characterized as focal tonic. There are no reports of generalized tonic seizures. The seizures are typically brief and last from one to three minutes. Although most are self-limited, some do evolve to seizures that are prolonged. In addition, the seizures usually recur during a period of 24 to 48 hours; only rarely do they persist beyond that period.",
"   </p>",
"   <p>",
"    The ictal EEG is not distinctive from other electrical or electroclinical seizure types.",
"   </p>",
"   <p>",
"    The character of the interictal EEG can be normal, discontinuous, or with multifocal sharp waves. The EEG pattern most closely associated with benign neonatal convulsions is referred to as \"theta pointu alternant\" [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/9\">",
"     9",
"    </a>",
"    ], and is characterized by nonreactive rhythmic slow activity, discontinuity, interhemispheric asynchrony, and multifocal sharp waves. While this EEG pattern is closely associated with benign neonatal convulsions, it is not specific; it is found in only about 60 percent of neonates with benign neonatal convulsions and has also been described in other disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal convulsions is currently considered a diagnosis of exclusion, since the initial clinical presentation may mimic that of infants with acute reactive seizures. Thus, an extensive evaluation for seizure etiology is necessary even when the suspicion for benign neonatal convulsions is considered high.",
"   </p>",
"   <p>",
"    Proposed diagnostic criteria include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apgar score greater than seven at one minute",
"     </li>",
"     <li>",
"      Typical interval between birth and seizure onset (four to six days)",
"     </li>",
"     <li>",
"      Normal neurologic examination before seizures and interictally",
"     </li>",
"     <li>",
"      Normal laboratory findings (eg, metabolic studies, neuroimaging, and cerebrospinal fluid analysis)",
"     </li>",
"     <li>",
"      No family history of neonatal seizures or post neonatal epilepsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy for benign neonatal convulsions is similar to that for other neonatal seizures, with AEDs acutely administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .) Some experts suggest that the use of AEDs be reserved for those infants who have prolonged seizures in light of the typical self-limited nature and brief duration of the seizures, as well as the generally good outcome associated with the natural history. If AEDs are used, they can usually be stopped once the infant is beyond the usual 24 to 48 hour period of recurrence risk.",
"   </p>",
"   <p>",
"    Infants with this disorder are thought to have a uniformly good outcome in terms of neurologic status, development, and post-neonatal epilepsy. However, some studies suggest a more variable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]; one meta-analysis found abnormalities in about 15 percent of infants followed from six months to six years, most with a transient \"psychomotor delay\" [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, the disorder may not always be as benign as its designation implies, suggesting that either there is an underlying etiology that has not yet been characterized, or that the seizures themselves may adversely affect the infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Benign familial neonatal convulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the first description of a family with neonatal seizures in several generations [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/13\">",
"     13",
"    </a>",
"    ], there has been great progress made in the characterization of the syndrome of benign familial neonatal convulsions (BFNC), its genetics, and biology [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/12\">",
"     12",
"    </a>",
"    ]. This syndrome has been reported to occur in 14.4 per 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of inheritance is autosomal dominant with penetration of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/15\">",
"     15",
"    </a>",
"    ]. Fifteen percent of those who carry a mutated gene may fail to show seizures. In addition, there may be some families with undetected mutations.",
"   </p>",
"   <p>",
"    Benign familial neonatal convulsions is now considered to be one of several epileptic disorders characterized as a channelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Two chromosome loci have been identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EBN1 syndrome, which is the most frequently encountered, there are deletions in the gene that encodes a voltage-gated potassium channel referred to as KCNQ2 on chromosome 20q [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/13,20-24\">",
"       13,20-24",
"      </a>",
"      ]. KCNQ2 mutations have also been identified in patients with more catastrophic epileptic encephalopathy syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a less frequently encountered EBN2 syndrome with a deletion of chromosome 8q24 that encodes another voltage-gated potassium channel referred to as KCNQ3 [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing is available in cases in which there is not a clear family history [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/28\">",
"     28",
"    </a>",
"    ]. Further information is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     file://www.genetests.org",
"    </a>",
"    . Counselling for genetic testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign familial neonatal convulsions are characterized by focal or multifocal clonic or tonic seizures, a family history of neonatal seizures, and no other neurologic abnormalities. The seizures typically occur within a few days to one week of life, although there is some variability in age at onset. Seizures are usually brief, but recurrence may occur until age two to three months, when spontaneous resolution typically occurs. The interictal EEG is usually normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for benign familial neonatal convulsions is similar to that for other neonatal seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The syndrome had been considered to be benign because initial reports suggested a relatively good outcome and no long term neurologic sequelae. However, subsequent studies have found a higher incidence of post neonatal epilepsy than in those without benign familial seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SEVERE SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the two syndromes just discussed are considered benign, the next two to be discussed - early (neonatal) myoclonic encephalopathy (EME) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/30\">",
"     30",
"    </a>",
"    ] and early infantile epileptic encephalopathy (EIEE) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/31\">",
"     31",
"    </a>",
"    ] - are often categorized as severe neonatal epilepsy syndromes because of their poor prognosis (",
"    <a class=\"graphic graphic_table graphicRef76108 \" href=\"UTD.htm?22/10/22700\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although EME and EIEE are considered distinct syndromes, they both exhibit a suppression-burst pattern on EEG. In addition, there may be considerable overlap between EME and EIEE in terms of diagnostic criteria and prognosis. Both of these syndromes have been associated with newly identified genetic mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Early myoclonic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early (neonatal) myoclonic encephalopathy (EME) has been referred to in the literature as myoclonic encephalopathy with neonatal onset, early myoclonic encephalopathy, neonatal myoclonic encephalopathy, and early myoclonic encephalopathy with epilepsy and has been most closely associated with Aicardi syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of onset is in the early neonatal period; there is no gender preponderance, and there have been some familial cases reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;EME has most often been associated with inborn errors of metabolism. The following disorders have been associated with EME:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-ketotic hyperglycemia",
"     </li>",
"     <li>",
"      D-glycemic acidemia",
"     </li>",
"     <li>",
"      Methylmalonic acidemia",
"     </li>",
"     <li>",
"      Propionic acidemia",
"     </li>",
"     <li>",
"      Hyperammonemia due to carbamyl phosphate synthetase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Congenital brain anomalies are thought to be an uncommon etiology for EME.",
"   </p>",
"   <p>",
"    The clinical picture of erratic myoclonus in an encephalopathic neonate with an EEG characterized as suppression-burst should prompt an evaluation for these etiologies. As already mentioned, there are a few reports of EME occurring in families. A number of cases are considered cryptogenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination is very abnormal at onset with all neonates experiencing an altered state of consciousness.",
"   </p>",
"   <p>",
"    In addition to the encephalopathy, seizure types are the basis of initial syndrome identification.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Segmental, fragmentary, or erratic myoclonic seizures are the earliest seizure type expressed, usually within the first few hours of life. These seizures are characterized by random, asynchronous, twitching of limb muscles, most often involving distal musculature. These are considered nonepileptic myoclonic seizures.",
"     </li>",
"     <li>",
"      Partial motor or focal clonic seizures may develop shortly after the appearance of the fragmentary myoclonic seizures, and may occur in association with the myoclonus or independently. The infant may eventually also experience generalized myoclonus.",
"     </li>",
"     <li>",
"      Repetitive tonic spasms may develop late in the course, between three and four months of age, after resolution of these other seizure types.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The EEG is helpful in diagnosis of EME. The background activity is charged as suppression-burst. The pattern may be present only in sleep, but it can also occur in all awake-sleep stages. The bursts are typically short (one to three seconds) and the periods of suppression are relatively long (two to 10 seconds). There is no associated EEG seizure activity when myoclonus is present, but EEG seizure activity is recorded when focal-clonic seizures occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the fragmentary myoclonus may eventually resolve over weeks or months, the focal motor seizures, if they do occur, tend to become refractory to antiepileptic drug therapy. The infants do not develop neurologically and tend not to acquire any developmental milestones. Approximately 50 percent of affected infants die, most within the first year of life.",
"   </p>",
"   <p>",
"    Efforts to treat both the seizures and the encephalopathy have been disappointing. Seizures, particularly the focal motor seizures, are typically treated with standard AEDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The encephalopathy and the associated fragmentary myoclonus are treated with etiology-specific therapies when available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Early infantile epileptic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early infantile epileptic encephalopathy (EIEE) has also been referred to as Ohtahara's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/31\">",
"     31",
"    </a>",
"    ]. It is a disorder with onset in infancy characterized by frequent tonic spasms and suppression-burst pattern on EEG. It is extremely rare, with less than 40 cases reported. There are some features of EIEE that are similar to EME, and there are also some distinctive characteristics (",
"    <a class=\"graphic graphic_table graphicRef76108 \" href=\"UTD.htm?22/10/22700\">",
"     table 2",
"    </a>",
"    ). The emerging consensus is that two syndromes have significantly overlapping features, and may be considered points along a spectrum of a single disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following types of abnormalities have been reported to occur in association with EIEE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Porencephaly",
"     </li>",
"     <li>",
"      Aicardi's syndrome (not the syndrome of EME referred to above)",
"     </li>",
"     <li>",
"      Cerebral atrophy",
"     </li>",
"     <li>",
"      Hemimegalencephaly",
"     </li>",
"     <li>",
"      Dentate-olivary dysplasia",
"     </li>",
"     <li>",
"      Migrational defects",
"     </li>",
"     <li>",
"      Mitochondrial disorders",
"     </li>",
"     <li>",
"      Genetic mutations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the majority of etiologic factors of EIEE consist of structural brain anomalies or lesions. Inborn errors of metabolism associated with EIEE are rare; when they do occur, nonketotic hyperglycemia has most often been identified. Genetic studies in individuals with EIEE have identified a number of gene mutations that appear to cause EIEE, including the KCNQ2 mutation that has been associated with benign familial neonatal convulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/25,32-38\">",
"     25,32-38",
"    </a>",
"    ]. Other associated mutations include SLC25A22 gene encoding a mitochondrial glutamate carrier; mutations in artistaless-related homeobox gene (ARX);",
"    <span class=\"nowrap\">",
"     mutation/deletions",
"    </span>",
"    of",
"    <span class=\"nowrap\">",
"     STXBP1/MUNC18-1;",
"    </span>",
"    and mutations in CDKL5 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/39\">",
"     39",
"    </a>",
"    ]. Genetic testing for some of these mutations is available [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/28\">",
"     28",
"    </a>",
"    ]. Further information is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     file://www.genetests.org",
"    </a>",
"    . Counselling for genetic testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .) Genetic analysis in five unrelated individuals with EIEE revealed de novo mutations in the gene encoding syntaxin binding protein 1, a protein involved in synaptic vesicle release [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/32\">",
"     32",
"    </a>",
"    ]. These findings contrast with EME, where etiologic factors are predominantly metabolic and rarely related to congenital brain anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onset is within the first two to three months of life. At onset the neurologic examination is abnormal with developmental delay, spasticity, and motor asymmetries. The predominant seizure type is tonic spasm, and within the spasm there is often a marked asymmetry of movement. Additional seizure types include focal motor seizures and hemiconvulsive seizures.",
"   </p>",
"   <p>",
"    Tonic spasms are the predominant seizure type in EIEE; they may occur in clusters, or they may occur intermittently in some patients. Tonic spasms occur early in the course of EIEE and erratic myoclonus typically does not occur at all. However, other myoclonic seizures may rarely occur in neonates with EIEE. This contrasts with the clinical features of EME, where erratic myoclonus is a characteristic early and tonic spasms a characteristic late seizure type.",
"   </p>",
"   <p>",
"    The characteristic background EEG pattern in EIEE (similar to EME) is that of suppression-burst with relatively prolonged bursts (two to six seconds) consisting of very high voltage activity (150-350uV) and relatively shorter periods of suppression (three to five seconds). The EEG shows associated synchronization when the tonic spasms occur, with an initial high-voltage slow wave and then generalized fast activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to the treatment of EIEE is similar to that of other types of neonatal seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, treatment of EIEE has been disappointing. There have been reported trials of steroid therapy (ACTH and corticosteroids), standard and newer AEDs (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"     zonisamide",
"    </a>",
"    ), and vitamin B6. There have also been case reports of treatment with hemispherectomy and cortical dysplasia resection.",
"   </p>",
"   <p>",
"    The overall outcome of EIEE is poor. Approximately 50 percent of affected patients die in infancy. Survivors have severe neurologic impairment. In most neonates, the EEG evolves to hypsarhythmia, which is typically asymmetrical. In the remainder, the EEG evolves to consist of multifocal or unifocal spikes. Rarely, the EEG evolves to a diffusely slow background.",
"   </p>",
"   <p>",
"    When considering prognosis, it is worth noting that EIEE (Ohtahara's syndrome) is the earliest of the age-dependent encephalopathies that include West syndrome and Lennox-Gastaut syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/40\">",
"     40",
"    </a>",
"    ]. The three share the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific age of onset",
"     </li>",
"     <li>",
"      Severe mental retardation",
"     </li>",
"     <li>",
"      Continuous epileptic EEG abnormalities",
"     </li>",
"     <li>",
"      The potential to evolve sequentially from syndrome to syndrome depending upon the age of the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, as the infant with Ohtahara's syndrome becomes a few months old, the patient may develop West syndrome and then in childhood develop Lennox-Gastaut syndrome with the associated seizure types and prognosis.",
"   </p>",
"   <p>",
"    West syndrome (also known as infantile spasms) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=see_link\">",
"     \"Etiology and pathogenesis of infantile spasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lennox-Gastaut syndrome is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H8#H8\">",
"     \"Epilepsy syndromes in children\", section on 'Lennox-Gastaut syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     DEND syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare form of severe neonatal epilepsy, the DEND syndrome (developmental delay, epilepsy, neonatal diabetes) is caused by an activating mutation in the KCNJ11 gene, which encodes the Kir6.2 subunit of the potassium ion channel [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/41\">",
"     41",
"    </a>",
"    ]. Oral sulfonylurea therapy appears to be more effective than insulin in controlling hyperglycemia, and can also lead to improved seizure control and psychomotor development [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35783/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Although described here, this has not yet been recognized formally by the ILAE as a neonatal epileptic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=see_link&amp;anchor=H12#H12\">",
"     \"Neonatal hyperglycemia\", section on 'Neonatal diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H123524714\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of neonatal seizures occur as acute reactive events in response to identifiable etiologic factors, four additional rare but distinct neonatal epileptic syndromes are well recognized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign neonatal convulsions, \"fifth day fits\", is an idiopathic neonatal seizure syndrome that occur in normal infants after an uneventful pregnancy, labor, and delivery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Benign neonatal convulsions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Seizures, usually brief, self-limited, unifocal clonic seizures, typically occur between days four and six of life. They usually recur within 24 to 48 hours, but not usually after that.",
"     </li>",
"     <li>",
"      This is a diagnosis of exclusion; other causes of neonatal seizures must be ruled out.",
"     </li>",
"     <li>",
"      Antiepileptic drugs may be administered if seizures are prolonged, but can be discontinued after 48 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign familial neonatal convulsions is an autosomal dominant inherited condition. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Benign familial neonatal convulsions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinically, this syndrome is characterized by focal or multifocal clonic or tonic seizures, a family history of neonatal seizures, and no other neurologic abnormalities.",
"     </li>",
"     <li>",
"      Genetic testing is available in cases in which there is not a clear family history.",
"     </li>",
"     <li>",
"      Some infants may require antiepileptic drug therapy; there is no long term neurologic sequelae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early myoclonic encephalopathy is most often associated with inborn errors of metabolism. A number of cases are considered cryptogenic. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Early myoclonic encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonates are encephalopathic at presentation, with nonepileptic myoclonus and multiple seizures types that typically begin within the first hours of life.",
"     </li>",
"     <li>",
"      EEG shows a suppression-burst pattern.",
"     </li>",
"     <li>",
"      The myoclonus typically subsides over weeks and months; focal motor seizures are often refractory to medical therapy.",
"     </li>",
"     <li>",
"      There is little neurologic development and mortality in the first year is approximately 50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early infantile epileptic encephalopathy (Ohtahara's syndrome) is a rare disorder typically associated with structural developmental brain anomalies. Some genetic syndromes have been identified. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Early infantile epileptic encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants present within the first two to three months with developmental delay, spasticity, and seizures, including tonic spasms and focal motor seizures.",
"     </li>",
"     <li>",
"      The interictal EEG shows suppression-burst pattern.",
"     </li>",
"     <li>",
"      Treatment with hormonal therapy, antiepileptic drugs, and epilepsy surgery is often unsuccessful.",
"     </li>",
"     <li>",
"      Half of patients die in infancy; survivors have severe neurologic impairment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/1\">",
"      Proposal for classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1985; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     Wolfe P. International classification of the epilepsies. In: Epilepsy: A Comprehensive Textbook, Engel J Jr, Pedley TA.  (Eds), Lippincott-Raven, Philadelphia 1997. p.773.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/3\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/4\">",
"      Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.",
"     </a>",
"    </li>",
"    <li>",
"     Mizrahi EM, Watanabe K. Symptomatic neonatal seizures. In: Epileptic syndromes in infancy, childhood and adolescence, 3rd, Roger J, Bureau M, Dravet CH, et al.  (Eds), John Libbey, 2002. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/6\">",
"      Goldberg HJ, Sheehy EM. Fifth day fits: an acute zinc deficiency syndrome? Arch Dis Child 1982; 57:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/7\">",
"      Herrmann B, Lawrenz-Wolf B, Seewald C, et al. [5th day convulsions of the newborn infant in rotavirus infections]. Monatsschr Kinderheilkd 1993; 141:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/8\">",
"      Ishii A, Fukuma G, Uehara A, et al. A de novo KCNQ2 mutation detected in non-familial benign neonatal convulsions. Brain Dev 2009; 31:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/9\">",
"      Dehan M, Quillerou D, Navelet Y, et al. [Convulsions in the fifth day of life: a new syndrome?]. Arch Fr Pediatr 1977; 34:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/10\">",
"      Okumura A, Watanabe K, Negoro T, et al. Long-term follow-up of patients with benign partial epilepsy in infancy. Epilepsia 2006; 47:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/11\">",
"      Auvin S, Pandit F, De Bellecize J, et al. Benign myoclonic epilepsy in infants: electroclinical features and long-term follow-up of 34 patients. Epilepsia 2006; 47:387.",
"     </a>",
"    </li>",
"    <li>",
"     Plouin P, Anderson VE. Benign familial and non-familial neonatal seizures. In: Epileptic Syndromes in Infancy, Childhood and Adolescence, Roger J, Bureau M, Dravet CH, et al.  (Eds), John Libbey &amp; Company, 2005. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/13\">",
"      Quattlebaum TG. Benign familial convulsions in the neonatal period and early infancy. J Pediatr 1979; 95:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/14\">",
"      Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr 1999; 134:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/15\">",
"      Cunniff C, Wiedlin N, Jones KL. Autosomal dominant benign neonatal seizures. Am J Med Genet 1988; 30:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/16\">",
"      Noebels JL. Ion Channelopathies and Heritable Epilepsy. News Physiol Sci 1998; 13:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/17\">",
"      Noebels JL. Modeling human epilepsies in mice. Epilepsia 2001; 42 Suppl 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/18\">",
"      Leppert M, Singh N. Benign familial neonatal epilepsy with mutations in two potassium channel genes. Curr Opin Neurol 1999; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/19\">",
"      Leppert M. Novel K+ channel genes in benign familial neonatal convulsions. Epilepsia 2000; 41:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/20\">",
"      Leppert M, Anderson VE, Quattlebaum T, et al. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989; 337:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/21\">",
"      Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/22\">",
"      Claes LR, Ceulemans B, Audenaert D, et al. De novo KCNQ2 mutations in patients with benign neonatal seizures. Neurology 2004; 63:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/23\">",
"      Zara F, Specchio N, Striano P, et al. Genetic testing in benign familial epilepsies of the first year of life: Clinical and diagnostic significance. Epilepsia 2013; 54:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/24\">",
"      Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/25\">",
"      Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012; 71:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/26\">",
"      Ryan SG, Wiznitzer M, Hollman C, et al. Benign familial neonatal convulsions: evidence for clinical and genetic heterogeneity. Ann Neurol 1991; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/27\">",
"      Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/28\">",
"      Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies--report of the ILAE Genetics Commission. Epilepsia 2010; 51:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/29\">",
"      Ronen GM, Rosales TO, Connolly M, et al. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993; 43:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/30\">",
"      Aicardi J, Goutieres F. [Neonatal myoclonic encephalopathy (author's transl)]. Rev Electroencephalogr Neurophysiol Clin 1978; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/31\">",
"      Ohtahara, S. Clinico-electrical delineation of epileptic encephalopathies in childhood. Asian Med J 1978; 21:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/32\">",
"      Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008; 40:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/33\">",
"      Mei D, Marini C, Novara F, et al. Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy. Epilepsia 2010; 51:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/34\">",
"      Guerrini R, Moro F, Kato M, et al. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology 2007; 69:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/35\">",
"      Bahi-Buisson N, Girard B, Gautier A, et al. Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/36\">",
"      Kato M, Saitoh S, Kamei A, et al. A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet 2007; 81:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/37\">",
"      Saitsu H, Kato M, Okada I, et al. STXBP1 mutations in early infantile epileptic encephalopathy with suppression-burst pattern. Epilepsia 2010; 51:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/38\">",
"      Pavone P, Spalice A, Polizzi A, et al. Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 2012; 34:459.",
"     </a>",
"    </li>",
"    <li>",
"     Mizrahi EM, Milh M. Early severe neonatal and infantile epileptic encephalopathies. In: Epileptic Syndromes in Infancy, Childhood and Adolescence, 5th, Bureau M, Genton P, Dravet C.  (Eds), Libbey Eurotex, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/40\">",
"      Yamatogi Y, Ohtahara S. Severe epilepsy with multiple independent spike foci. J Clin Neurophysiol 2003; 20:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/41\">",
"      Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/42\">",
"      Shimomura K, H&ouml;rster F, de Wet H, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007; 69:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/43\">",
"      Pearson ER, Flechtner I, Nj&oslash;lstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35783/abstract/44\">",
"      Landau Z, Wainstein J, Hanukoglu A, et al. Sulfonylurea-responsive diabetes in childhood. J Pediatr 2007; 150:553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6198 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35783=[""].join("\n");
var outline_f34_60_35783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H123524714\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE REACTIVE SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BENIGN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Benign neonatal convulsions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Benign familial neonatal convulsions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SEVERE SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Early myoclonic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Early infantile epileptic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DEND syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H123524714\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/34/7724\" title=\"table 1\">",
"      Etiologies of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22700\" title=\"table 2\">",
"      Comparison between EME and EIEE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=related_link\">",
"      Clinical features and electrodiagnosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=related_link\">",
"      Etiology and pathogenesis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=related_link\">",
"      Etiology and prognosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35784="Clinical manifestations and initial surgical approach to patients with malignant gliomas";
var content_f34_60_35784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35784/contributors\">",
"     William T Curry, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35784/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/60/35784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and glioblastoma (GBM) based upon their histopathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations, pretreatment prognostic factors, and initial surgical approach to patients with malignant gliomas will be reviewed here.",
"   </p>",
"   <p>",
"    Other patient management topics that are covered separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with suspected brain tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adjuvant radiation therapy and chemotherapy following initial surgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrent malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link\">",
"       \"Management of recurrent malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anaplastic oligodendroglial tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=see_link\">",
"       \"Treatment of oligodendroglial tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elderly patients (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=see_link\">",
"       \"Management of malignant gliomas in elderly patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Experimental approaches for malignant glioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"       \"Experimental treatment approaches for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of malignant gliomas are dependent upon the location and size of the lesion and are similar to those produced by other primary and metastatic brain tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of symptoms produced by malignant gliomas was illustrated by a series of 565 glioma patients (147 grade III and 418 grade IV) reported by the Glioma Outcomes Project (",
"    <a class=\"graphic graphic_table graphicRef65078 \" href=\"UTD.htm?40/21/41307\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache occurred in 53 to 57 percent of cases.",
"     </li>",
"     <li>",
"      Seizures were present in 56 percent of patients with grade III lesions, compared with 23 percent of those with grade IV lesions.",
"     </li>",
"     <li>",
"      Other symptoms seen at presentation in 20 percent or more of patients included memory loss, motor weakness, visual symptoms, language deficit, and cognitive and personality changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of more advanced neurologic deficits and findings were substantially lower than in older series. This presumably reflects earlier diagnosis with modern radiologic imaging techniques.",
"   </p>",
"   <p>",
"    Rarely, malignant gliomas can present with meningeal dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/3\">",
"     3",
"    </a>",
"    ]. This finding is more commonly diagnosed later in the natural history of the disease or at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Presenting symptoms of meningeal gliomatosis are back pain with or without radicular symptoms, mental status changes, cranial nerve palsies, myelopathy, or cauda equina syndrome, and headache with symptomatic hydrocephalus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important prognostic factors affecting the response to subsequent treatment are age, tumor grade (anaplastic glioma versus GBM), and Karnofsky performance status (KPS, (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ))&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. The extent of initial surgical resection also appears to influence prognosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Extent of resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The impact of these clinical factors on outcome was illustrated in a study of 832 patients with GBM in which the outcome was analyzed using recursive partitioning analysis (RPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/12\">",
"     12",
"    </a>",
"    ]. Four prognostic groups were identified based upon age at presentation, tumor location, KPS, and extent of surgery. The different survival durations for these groups are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef75280 \" href=\"UTD.htm?23/7/23678\">",
"     figure 1",
"    </a>",
"    ). A similar analysis in older adults age &ge;70 identified four prognostic subgroups based on age, extent of surgery (biopsy versus resection), and KPS; median survival ranged from 2.3 months in subgroup IV (biopsy only, KPS &lt;70) to 9.3 months in subgroup I (surgical resection, age &lt;75.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with newly diagnosed GBM, nomograms have been developed to estimate both median survival and two-year survival probability, and to assist in decision making for individual patients (",
"    <a class=\"graphic graphic_figure graphicRef78955 \" href=\"UTD.htm?17/36/17999\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/13\">",
"     13",
"    </a>",
"    ]. Prognostic factors incorporated into these nomograms include patient age, extent of resection, use of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    , mental status, and corticosteroid use at baseline. These nomograms were based upon the 571 patients enrolled in the temozolomide adjuvant chemotherapy trial [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beyond histologic grade and clinical parameters, various molecular alterations within gliomas have been recognized, some of which carry prognostic significance. The most important are mutations in isocitrate dehydrogenase-1 (",
"    <em>",
"     IDH1",
"    </em>",
"    ) and",
"    <em>",
"     IDH2",
"    </em>",
"    , which are present in approximately 50 percent of anaplastic gliomas and five percent of glioblastomas and predict significantly improved overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathogenesis and biology of malignant gliomas\", section on 'Prognostic impact of molecular alterations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tissue diagnosis in patients with a presumed malignant glioma is essential. This can be accomplished either at the time of surgical resection or in a separate procedure known as a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stereotactic biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined use of computerized imaging and stereotactic framing devices has allowed neurosurgeons to perform deep brain biopsies with accurate tumor localization. In the 1990s, \"frameless\" stereotactic devices were developed to provide continuous intraoperative localization and are used in most major medical centers. Frameless stereotaxy establishes a computerized link between the preoperative three-dimensional tumor volume and the surface landmarks of the patient. This link permits the neurosurgeon to be aware of the three-dimensional position of surgical instruments within the intracranial space during the biopsy based upon the preoperative imaging, with an accuracy of 1 mm within the intracranial space [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stereotactic image-guided brain biopsy is an accurate and safe diagnostic procedure in patients with focal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. In a report of 125 frameless stereotactic biopsies in which 86 were MRI-directed and 39 CT-directed, a definitive diagnosis was obtained in 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/19\">",
"     19",
"    </a>",
"    ]. In a second series of 141 biopsies, the CT- or MRI-guided stereotactic approach was associated with significantly fewer nondiagnostic biopsies (9 versus 18 percent with freehand CT-guided biopsy) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/20\">",
"     20",
"    </a>",
"    ]. Morbidity was similar with the two procedures (6 versus 5 percent). Although rare, tumor seeding along the stereotactic biopsy tract has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The procedure-related mortality is 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/20,25,26\">",
"     20,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) have been used to identify metabolically active areas of tumor, thereby increasing the accuracy of stereotactic brain biopsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PET &mdash; Integration of PET using 18F-labeled fluorodeoxyglucose (FDG-PET)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      L-[methyl-11C] methionine (MET-PET) into the planning of stereotactic brain biopsy may increase the diagnostic yield.",
"      <br/>",
"      <br/>",
"      This was illustrated by a series in which 32 patients with gliomas underwent a total of 70 stereotactic biopsies, guided by the results of FDG-PET and MET-PET [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/27\">",
"       27",
"      </a>",
"      ]. Of the 61 biopsies directed at MET-PET positive sites, all were diagnostic for tumor. Areas of highest MET-PET tracer uptake corresponded to the strongest FDG-PET signal. MET-PET provided greater tumor sensitivity. All nondiagnostic biopsies were obtained in MET-PET negative areas, indicating high specificity for image-guided biopsies.",
"      <br/>",
"      <br/>",
"      In a similar study using only FDG-PET, 90 stereotactic biopsies were performed in 36 patients; 55 were based upon FDG-PET-defined targets, while 35 were based on CT-defined targets [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/28\">",
"       28",
"      </a>",
"      ]. Histologic diagnosis was obtained in all patients, but six nondiagnostic samples were obtained from CT-defined targets.",
"     </li>",
"     <li>",
"      MRS &mdash; Magnetic resonance spectroscopy is increasingly being utilized as a diagnostic and localization technique for brain tumors, particularly in target selection during brain biopsy, and to estimate the histopathologic grade of a tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical presentation and diagnosis of brain tumors\", section on 'Magnetic resonance spectroscopy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment for malignant gliomas is resection. Maximal resection with preservation of neurologic function is an important goal in the initial management of patients with malignant gliomas, and the extent of surgery must be balanced with preservation of neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/7,32-37\">",
"     7,32-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available evidence suggests that aggressive resection is associated with improved functional status and possibly with prolonged survival. Various preoperative and intraoperative advances are being incorporated into patient management to facilitate these goals. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Extent of resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A review of over 38,000 surgical admissions for supratentorial brain tumors from the Nationwide Inpatient Sample between 1988 and 2000 showed three important trends: decreasing inpatient mortality over time for brain tumor operations, centralization of care with higher volume centers performing an ever larger percentage of all such surgeries, and reduced mortality at high volume hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/38\">",
"     38",
"    </a>",
"    ]. For craniotomy, mortality at hospitals with five or fewer admissions per year was 4.5 percent, compared to 1.5 percent at hospitals with 42 or more admissions per year. It is not known whether these trends affect long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Preoperative imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative PET scanning and functional or echo planar MRI may optimize tumor volume definition and minimize operative injury to eloquent (speech) areas by allowing preoperative definition of affected and normal brain areas and functional mapping of brain tissue, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In addition to localization of functional \"cortical areas\" such as motor cortex via functional MRI, diffusion tensor imaging now enables the visualization of \"subcortical\" tracts that carry eloquent task information from speech, motor, and visual pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of PET was illustrated in a series of 103 patients with brain tumors, 40 of which were malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/39\">",
"     39",
"    </a>",
"    ]. FDG-PET and MET-PET images were fused with MRI data to guide maximal surgical resection of tumor. Overall, PET contributed to a change of the tumor resection target in 80 percent of patients. Whether these altered resection volumes have prognostic significance is unknown, but the ability to target hypermetabolic areas in surgery allows prioritization that might have clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intraoperative techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several intraoperative techniques are used to improve the extent of surgical resection while minimizing collateral damage to normal brain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For tumors located in eloquent areas, awake craniotomy combining frameless computer-guided stereotaxis with intraoperative cortical stimulation and repetitive neurologic and language assessments may facilitate aggressive resection while minimizing postoperative neurologic dysfunction. Traditionally this approach has used repetitive testing, with resection discontinued at the first evidence of neurologic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/43\">",
"       43",
"      </a>",
"      ]. Alternatively, local stimulation has been used to induce language dysfunction, with tumor resection proceeding only in areas not involving language centers [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Specially designed operating rooms that are equipped with computerized tomography (CT) or MRI scanners can guide the resection in \"real time\". In contrast to frame-based or frameless stereotaxy, this advancement allows actual assessment of tumor volume in its current anatomic location, rather than relying on preoperative data [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/45\">",
"       45",
"      </a>",
"      ]. Intraoperative imaging is used to identify residual tumor after the initial resection and thus can be used to guide further surgery.",
"      <br/>",
"      <br/>",
"      The effectiveness of intraoperative MRI was assessed in a trial in which 58 patients were randomly assigned to surgery with or without intraoperative MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/46\">",
"       46",
"      </a>",
"      ]. At surgery, 49 patients had malignant gliomas and were evaluable. In 8 of 24 cases using intraoperative MRI, imaging revealed residual tumor and led to additional tumor resection. Overall, significantly more patients managed with intraoperative MRI had a complete resection compared with those managed without MRI (23 of 24 [96 percent] versus 17 of 25 [68 percent], p=0.02). There was no increase in neurologic deficits with this more aggressive surgical approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these advances in surgical techniques, local recurrences are frequent even in patients undergoing an apparently complete removal of the tumor. Malignant gliomas are characterized by poorly defined tumor margins with infiltration of neoplastic cells along white matter fibers and the perivascular spaces, which can extend well beyond the tumor margin as defined by the surgeon or by radiographic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extent of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect on survival of maximal resection is uncertain. Although a number of studies failed to demonstrate a benefit with more extensive surgical resection (either subtotal resection versus biopsy, or complete versus subtotal resection) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/8,50-53\">",
"     8,50-53",
"    </a>",
"    ], other reports suggested that maximal resection (particularly gross total resection) does lengthen survival [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/7,9,10,46,54-59\">",
"     7,9,10,46,54-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strongest data come from a European trial, in which fluorescence-guided resection with 5-aminolevulinic acid (ALA) was studied as a way to improve the extent of resection in a trial in which 270 patients with newly diagnosed GBM were randomly assigned to resection with either ALA or white light [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Complete resection was achieved in significantly more patients with fluorescence guided surgery than with white light (90 of 139 [65 percent] versus 47 of 131 [29 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/54\">",
"     54",
"    </a>",
"    ]. Furthermore, survival was significantly prolonged in those patients who had a complete resection compared to those with a lesser resection (17.7 versus 12.9, and 13.7 versus 10.4 months, respectively, for recursive partitioning analysis (RPA) classes IV and V).",
"   </p>",
"   <p>",
"    Similar conclusions were drawn from earlier a number of earlier studies, supporting the survival advantage with complete surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/7,9,56\">",
"     7,9,56",
"    </a>",
"    ]. Even in reports that question the use of extensive surgery, there is a trend favoring resection over biopsy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/8,52\">",
"     8,52",
"    </a>",
"    ]. Furthermore, many of the studies that did not demonstrate a benefit from maximal tumor resection are from an era of suboptimal brain imaging (ie, prior to the current availability of high-resolution MRI, and preceding the complementary use of functional imaging and modern intraoperative techniques).",
"   </p>",
"   <p>",
"    A survival benefit may exist for significant subtotal resection of the gadolinium-enhancing portions of the tumor. The volumetric extent of glioblastoma resection has been studied in relation to overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/60\">",
"     60",
"    </a>",
"    ]. The cut-point for survival benefit was at 78 percent extent of resection; above 78 percent, further resection correlated with enhanced survival.",
"   </p>",
"   <p>",
"    Other benefits of maximal resection rather than biopsy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection rather than biopsy provides a larger, more representative sample for detailed analysis, thereby increasing the likelihood of an accurate diagnosis, which can help to direct further therapy.",
"     </li>",
"     <li>",
"      Maximal resection facilitates rapid symptomatic improvement. Patients who undergo complete resection appear to have fewer neurologic complications and no greater risk of being neurologically impaired than patients managed with either biopsy or less extensive resection [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/34\">",
"       34",
"      </a>",
"      ]. In addition, debulking surgery may facilitate rapid tapering and discontinuation of corticosteroids, thereby reducing the likelihood of steroid-related complications.",
"     </li>",
"     <li>",
"      Substantial tumor debulking prior to RT or chemotherapy may improve the response to postoperative adjuvant treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/36,61\">",
"       36,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADJUVANT RADIATION THERAPY AND CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant gliomas are rapidly progressive tumors that are best managed with a combined modality approach, incorporating maximal surgical resection, adjuvant postoperative radiation therapy, and adjuvant chemotherapy. Postoperative management with radiation therapy and chemotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701994156\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal clinical trials that define the optimal frequency for follow-up after treatment. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that a repeat MRI should be obtained in patients with a malignant glioma about two to six weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=see_link\">",
"       \"Patient information: Brain cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/34/6690?source=see_link\">",
"       \"Patient information: Astrocytoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/28/22978?source=see_link\">",
"       \"Patient information: Glioblastoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"       \"Patient information: Primary low-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=see_link\">",
"       \"Patient information: Meningioma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas and glioblastoma (GBM) based upon their histopathologic features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A histologic diagnosis is required for optimal treatment of patients with brain tumors. This can be accomplished either at the time of surgical resection or in a separate procedure known as a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed malignant glioma (including both GBM and astrocytic astrocytoma), we recommend maximal surgical resection consistent with preservation of neurologic function rather than biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although gross total resection is preferred whenever possible, subtotal resection or just a stereotactic biopsy may be required depending upon the location and extent of the tumor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed glioblastoma (GBM), we recommend combined adjuvant radiation therapy (RT) and chemotherapy following surgery or biopsy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed anaplastic astrocytoma, we generally suggest adjuvant radiation therapy (RT) and chemotherapy following surgery or biopsy, using the same approach to RT and chemotherapy as in patients with GBM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations for the management of patients with newly diagnosed glioblastoma are consistent with guidelines published by the American Association of Neurological Surgeons and the Congress of Neurological Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35784/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/1\">",
"      Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/2\">",
"      Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/3\">",
"      Wheen LC, Anderson NE, Baker PC, et al. Leptomeningeal infiltration as the presenting manifestation of a malignant glioma. J Clin Neurosci 2006; 13:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/4\">",
"      Wagner S, Benesch M, Berthold F, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 2006; 95:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/5\">",
"      Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: a review of 12 cases. Ann Neurol 1980; 8:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/6\">",
"      Narin O, Drappatz J, Doherty LM, et al. Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol 2007; 25:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/7\">",
"      Dinapoli RP, Brown LD, Arusell RM, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993; 11:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/8\">",
"      Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/9\">",
"      Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993; 78:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/10\">",
"      Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/11\">",
"      Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/12\">",
"      Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004; 6:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/13\">",
"      Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/14\">",
"      Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008; 64:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/15\">",
"      Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012; 118:5595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/16\">",
"      Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/17\">",
"      Patel N, Sandeman D. A simple trajectory guidance device that assists freehand and interactive image guided biopsy of small deep intracranial targets. Comput Aided Surg 1997; 2:186.",
"     </a>",
"    </li>",
"    <li>",
"     Greenberg HS, Chandler WF, Sandler HS. Brain Tumors (Contemporary Neurology Series 54), Oxford University Press, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/19\">",
"      Paleologos TS, Dorward NL, Wadley JP, Thomas DG. Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases. Neurosurgery 2001; 49:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/20\">",
"      Wen DY, Hall WA, Miller DA, et al. Targeted brain biopsy: a comparison of freehand computed tomography-guided and stereotactic techniques. Neurosurgery 1993; 32:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/21\">",
"      Robbins PD, Yu LL, Lee M, et al. Stereotactic biopsy of 100 intracerebral lesions at Sir Charles Gairdner Hospital. Pathology 1994; 26:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/22\">",
"      Chandrasoma PT, Smith MM, Apuzzo ML. Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery 1989; 24:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/23\">",
"      Steinmetz MP, Barnett GH, Kim BS, et al. Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature. J Neurooncol 2001; 55:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/24\">",
"      Perrin RG, Bernstein M. Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy. J Neurooncol 1998; 36:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/25\">",
"      Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 1994; 81:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/26\">",
"      Bernays RL, Kollias SS, Khan N, et al. Histological yield, complications, and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imaging. J Neurosurg 2002; 97:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/27\">",
"      Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004; 45:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/28\">",
"      Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 1995; 82:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/29\">",
"      McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/30\">",
"      Hall WA, Liu H, Maxwell RE, Truwit CL. Influence of 1.5-Tesla intraoperative MR imaging on surgical decision making. Acta Neurochir Suppl 2003; 85:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/31\">",
"      Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/32\">",
"      Black PM. Brain tumors. Part 1. N Engl J Med 1991; 324:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/33\">",
"      Berger MS. Malignant astrocytomas: surgical aspects. Semin Oncol 1994; 21:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/34\">",
"      Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988; 38:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/35\">",
"      FRANKEL SA, GERMAN WJ. Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 1958; 15:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/36\">",
"      Salcman M. Surgical resection of malignant brain tumors: who benefits? Oncology (Williston Park) 1988; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/37\">",
"      Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/38\">",
"      Barker FG 2nd, Curry WT Jr, Carter BS. Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 2005; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/39\">",
"      Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006; 104:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/40\">",
"      Krishnan R, Raabe A, Hattingen E, et al. Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome. Neurosurgery 2004; 55:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/41\">",
"      Ganslandt O, Buchfelder M, Hastreiter P, et al. Magnetic source imaging supports clinical decision making in glioma patients. Clin Neurol Neurosurg 2004; 107:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/42\">",
"      Kamada K, Todo T, Masutani Y, et al. Visualization of the frontotemporal language fibers by tractography combined with functional magnetic resonance imaging and magnetoencephalography. J Neurosurg 2007; 106:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/43\">",
"      Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 2001; 76:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/44\">",
"      Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med 2008; 358:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/45\">",
"      Kubben FL, ter Meulen KJ, Schijns EM, et al.. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/46\">",
"      Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/47\">",
"      Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/48\">",
"      Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/49\">",
"      Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/50\">",
"      Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988; 22:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/51\">",
"      Duncan GG, Goodman GB, Ludgate CM, Rheaume DE. The treatment of adult supratentorial high grade astrocytomas. J Neurooncol 1992; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/52\">",
"      Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993; 78:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/53\">",
"      Sandberg-Wollheim M, Malmstr&ouml;m P, Str&ouml;mblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/54\">",
"      Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/55\">",
"      Pichlmeier U, Bink A, Schackert G, et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008; 10:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/56\">",
"      Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/57\">",
"      Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988; 6:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/58\">",
"      Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/59\">",
"      Bucci MK, Maity A, Janss AJ, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 2004; 101:817.",
"     </a>",
"    </li>",
"    <li>",
"     Sanai, N, Mirzadeh, Z, Polley, M, Berger, M. The Value of Glioblastoma Extent of Resection: A Volumetric Analysis of 500 Patients (abstract). Presented at Am Assoc Neuro Surg meeting, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/61\">",
"      Glantz MJ, Burger PC, Herndon JE 2nd, et al. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 1991; 41:1741.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/63\">",
"      Fadul CE, Wen PY, Kim L, Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 2008; 89:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/64\">",
"      Buatti J, Ryken TC, Smith MC, et al. Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 2008; 89:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35784/abstract/65\">",
"      Ryken TC, Frankel B, Julien T, Olson JJ. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol 2008; 89:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5228 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35784=[""].join("\n");
var outline_f34_60_35784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stereotactic biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Preoperative imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intraoperative techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extent of resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADJUVANT RADIATION THERAPY AND CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701994156\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5228|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/7/23678\" title=\"figure 1\">",
"      Survival estimates for glioblastoma by risk group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/36/17999\" title=\"figure 2\">",
"      Glioblastoma nomogram for survival prediction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5228|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/21/41307\" title=\"table 1\">",
"      Symptoms of GBM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15029?source=related_link\">",
"      Management of malignant gliomas in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=related_link\">",
"      Pathogenesis and biology of malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/34/6690?source=related_link\">",
"      Patient information: Astrocytoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=related_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/28/22978?source=related_link\">",
"      Patient information: Glioblastoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=related_link\">",
"      Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=related_link\">",
"      Treatment of oligodendroglial tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35785="Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease";
var content_f34_60_35785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/60/35785/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/60/35785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with kidney disease may have a variety of different clinical presentations. Some have symptoms or signs that are directly referable to the kidney (hematuria, flank pain) or to associated extrarenal manifestations (edema, hypertension, signs of uremia), but many patients are asymptomatic and are noted on routine examination to have an elevated serum creatinine concentration or an abnormal urinalysis (such as microscopic hematuria or proteinuria). Specific disorders are more likely to be either acute or chronic in duration, thereby narrowing the differential diagnosis among patients presenting with similar clinical findings related to the kidney.",
"   </p>",
"   <p>",
"    An overview of the diagnostic approach to the patient with kidney disease is presented in this topic. There are",
"    <strong>",
"     two major components",
"    </strong>",
"    to this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of renal function by estimation of the glomerular filtration rate (GFR), initially by measurement of the serum creatinine concentration and, in patients with stable kidney function, the use of formulas that provide reasonable, but not precise, estimates of GFR. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Assessment of kidney function'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Careful examination of the urine (by both qualitative chemical tests and microscopic examination), since the urinary findings narrow the differential (",
"      <a class=\"graphic graphic_table graphicRef56160 \" href=\"UTD.htm?37/51/38715\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Urinary findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology of chronic kidney disease and indications for screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link\">",
"     \"Epidemiology of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28966?source=see_link\">",
"     \"Screening for chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428589108\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the terms acute and chronic renal failure were commonly used. At present, acute renal failure has been replaced by acute kidney injury and chronic renal failure has been replaced by chronic kidney disease, in part because many patients have mild to moderate disease, not renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link&amp;anchor=H27258481#H27258481\">",
"     \"Definition and staging of chronic kidney disease\", section on 'Definition of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definitions of what constitutes acute, rapidly progressive, and chronic kidney disease and how to make the distinction are presented below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Disease duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAJOR CAUSES OF KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of acute kidney injury or chronic kidney disease are traditionally classified by that portion of the renal anatomy that is most affected [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/1\">",
"     1",
"    </a>",
"    ]. Renal function is based upon four sequential steps, which are isolated to specific areas of the kidney or surrounding structures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, blood from the renal arteries and their subdivisions is delivered to the glomeruli.",
"     </li>",
"     <li>",
"      The glomeruli form an ultrafiltrate of plasma that is nearly free of protein and blood elements and that flows into the renal tubules.",
"     </li>",
"     <li>",
"      The tubules reabsorb",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      secrete solutes (eg, sodium, potassium, hydrogen, urea, and creatinine) and reabsorb almost of all of the filtered water.",
"     </li>",
"     <li>",
"      The final tubular fluid, the urine, leaves the kidney, draining sequentially into the renal pelvis, ureter, and bladder, from which it is excreted through the urethra.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of solute and water excretion in normal individuals is directly related to intake or, with urea and creatinine, the rate of endogenous production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney disease can be caused by any process that interferes with any of the above structures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functions. Identifying prerenal (reduced renal perfusion) and postrenal (obstructive) disease is particularly important because they may be readily reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prerenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major causes of reduced renal perfusion are volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relative hypotension. This may result from true volume depletion due to bleeding, gastrointestinal, urinary, or cutaneous losses, or from effective circulating volume depletion in heart failure (cardiorenal syndrome), cirrhosis (hepatorenal syndrome), or shock, disorders in which the extracellular fluid volume may be normal or, in edematous patients, increased but tissue perfusion is reduced due to decreased cardiac output in heart failure, splanchnic venous pooling and systemic vasodilation in cirrhosis, or systemic vasodilation in distributive shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H914954238#H914954238\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Causes of prerenal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=see_link&amp;anchor=H2022685#H2022685\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Reduced renal perfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H2#H2\">",
"     \"Hepatorenal syndrome\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H18#H18\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive shock'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=see_link\">",
"     \"Chapter 8A: Effective circulating volume and the steady state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prerenal disease due to true volume depletion is most commonly associated with an acute time course. In contrast, prerenal disease due to chronic heart failure or cirrhosis is typically associated with a persistent reduction in renal function. Among patients with chronic kidney disease, the addition of a prerenal process can result in a further impairment in kidney function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular diseases affecting the kidney can be divided into those that produce acute and chronic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common",
"      <strong>",
"       acute",
"      </strong>",
"      renal vascular disease is probably vasculitis (eg, Wegener's granulomatosis). Less common etiologies include thromboembolic disease, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura",
"      <span class=\"nowrap\">",
"       (HUS/TTP),",
"      </span>",
"      malignant hypertension, and scleroderma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H2#H2\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Clinical patterns of glomerular disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=see_link\">",
"       \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H3#H3\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"       \"Scleroderma renal crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common",
"      <strong>",
"       chronic",
"      </strong>",
"      renal vascular diseases are benign hypertensive nephrosclerosis, unilateral or bilateral renal artery stenosis, and atheroembolic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"       \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=see_link\">",
"       \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous idiopathic and secondary (due to neoplasia, autoimmunity, drugs, genetic abnormalities, and infections) disorders that produce glomerular disease. Two general patterns (with considerable overlap in some diseases) are seen (",
"    <a class=\"graphic graphic_table graphicRef62131 \" href=\"UTD.htm?34/13/35036\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nephritic pattern, which is associated with inflammation on histologic examination and produces an active urine sediment with red cells, white cells, granular and often red cell and other cellular casts, and a variable degree of proteinuria that can reach the nephrotic range (greater than 3.5",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours).",
"     </li>",
"     <li>",
"      A nephrotic pattern, which is not associated with inflammation on histologic examination and is associated with proteinuria, usually in the nephrotic range, and an inactive urine sediment with few cells or casts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both patterns can present with an acute or insidious time course, and elements of both may be also seen simultaneously or sequentially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tubular and interstitial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with vascular disease, tubular and interstitial (tubulointerstitial) diseases affecting the kidney can be divided into acute and chronic diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common",
"      <strong>",
"       acute",
"      </strong>",
"      tubulointerstitial diseases are acute tubular necrosis, which typically occurs in hospitalized patients, acute interstitial nephritis, which is often drug-induced, and cast nephropathy in multiple myeloma. Other causes that should be considered in the appropriate setting are moderate to severe hypercalcemia, tumor lysis syndrome following chemotherapy, and acute phosphate nephropathy following a phosphate-containing bowel preparation prior to colonoscopy or surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"       \"Types of renal disease in multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations of hypercalcemia\", section on 'Renal insufficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"       \"Acute phosphate nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common",
"      <strong>",
"       chronic",
"      </strong>",
"      tubulointerstitial disease is polycystic kidney disease. Other causes include nephrocalcinosis (most often due to hypercalcemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypercalciuria), sarcoidosis, Sj&ouml;gren's syndrome, reflux nephropathy in children and young adults, and medullary cystic kidney disease in families with a pattern of autosomal dominant inheritance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=see_link\">",
"       \"Nephrocalcinosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal disease in sarcoidosis\", section on 'Hypercalciuria and hypercalcemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link\">",
"       \"Renal disease in Sj&ouml;gren's syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"       \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obstructive uropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction to the flow of urine can occur anywhere in the urinary tract from the renal pelvis to the urethra. A reduction in glomerular filtration rate in patients without intrinsic renal disease requires bilateral obstruction (or unilateral obstruction in a single functioning kidney) and is most commonly due to prostatic disease (hyperplasia or cancer) or metastatic cancer. The time course can be acute or chronic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Relative frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the relative frequency of the different causes of acute kidney injury (AKI, previously called acute renal failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In addition, the distribution may vary with the type of hospital (community versus referral), severity of underlying disease, and geographic region.",
"   </p>",
"   <p>",
"    A report from Madrid evaluated all 748 cases of AKI at 13 tertiary hospital centers [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/4\">",
"     4",
"    </a>",
"    ]. The most frequent causes were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute tubular necrosis (ATN) &mdash; 45 percent",
"     </li>",
"     <li>",
"      Prerenal disease &mdash; 21 percent",
"     </li>",
"     <li>",
"      Acute superimposed on chronic kidney disease &mdash; 13 percent (mostly due to acute tubular necrosis and prerenal disease)",
"     </li>",
"     <li>",
"      Urinary tract obstruction &mdash; 10 percent (most often older men with prostatic disease)",
"     </li>",
"     <li>",
"      Glomerulonephritis or vasculitis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Acute interstitial nephritis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Atheroemboli &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study from the Program to Improve Care in Acute Renal Disease (PICARD) examined the etiology of AKI in a sicker population of 618 patients in five intensive care units in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients had more than one possible cause. Over 70 percent of cases were thought to be due to postischemic ATN (including sepsis and hypotension). Other causes included prerenal disease (eg, hypovolemia, heart failure, and hepatorenal syndrome), contrast-induced nephropathy, and rhabdomyolysis. Some patients had two or more causes of AKI.",
"   </p>",
"   <p>",
"    AKI can occur in patients with underlying chronic kidney disease. Data are limited on the etiology of AKI in this setting. In a retrospective Chinese study of 104 such patients, AKI was attributed to drug-related",
"    <span class=\"nowrap\">",
"     ATN/acute",
"    </span>",
"    interstitial nephritis, prerenal disease, lupus nephritis flare, and malignant hypertension in 36, 24, 20, and 9 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of end-stage renal disease, although not verified histologically, is reported in multiple databases. In the 2006 Annual Report from the United States Renal Data System, the most common causes and their prevalence were diabetes (37 percent), hypertension (24 percent, almost all with no primary renal disease),",
"    <span class=\"nowrap\">",
"     glomerulonephritis/vasculitis",
"    </span>",
"    (19 percent), interstitial nephritis (5 percent), and polycystic kidney disease (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/8\">",
"     8",
"    </a>",
"    ]. Diabetes and hypertension are also the most common causes of non-end-stage chronic kidney disease in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRESENTING MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute kidney injury (AKI, previously called acute renal failure) or chronic kidney disease (CKD) can present with one or more of the following manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms and signs resulting directly from diminished kidney function, including edema, hypertension, flank pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased urine output.",
"     </li>",
"     <li>",
"      Symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of renal failure, including weakness and easy fatigability (often due in part to anemia), anorexia, vomiting, mental status changes, and seizures.",
"     </li>",
"     <li>",
"      Laboratory findings, including an elevation in the serum creatinine concentration, hyperkalemia, and, on urinalysis, albuminuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an abnormal urine sediment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Urinalysis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Incidental findings (eg, multiple renal cysts suggestive of polycystic kidney disease) on radiographic imaging performed for some other reason.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of certain symptoms or signs may suggest an underlying diagnosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic symptoms and findings, such as fever, arthralgias, and pulmonary lesions are suggestive of a systemic disease, such as vasculitis or lupus.",
"     </li>",
"     <li>",
"      Unilateral flank pain is most consistent with obstruction, renal infarction, or infection.",
"     </li>",
"     <li>",
"      The total absence of urine (anuria) is primarily observed with shock and is less often due to bilateral ureteral obstruction, or bilateral renal arterial obstruction (eg, dissecting aortic aneurysm).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A constellation of symptoms and signs may also favor a particular set of disorders. As examples, edema, hypertension, hematuria with red cell casts, and a rapidly rising serum creatinine concentration is almost certainly due to acute glomerulonephritis or renal vasculitis, while edema, heavy proteinuria, and little or no hematuria is indicative of a nonproliferative glomerular disease such as diabetic nephropathy, membranous nephropathy, or minimal change disease. Some other urinary findings are relatively nonspecific (eg, a normal or near normal urinalysis) and can be observed in a variety of disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H30#H30\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Correlation of urinary findings with kidney diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Disease duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important aspect of the evaluation of the patient with kidney disease is the determination of disease duration. The distinction between acute, rapidly progressive, and chronic kidney disease is arbitrary but the following definitions are often used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute",
"      </strong>",
"      &mdash; A rise in the serum creatinine concentration or an abnormal urinalysis that has developed within hours to days. The criteria for acute kidney injury include an increase in serum creatinine by 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or &ge;1.5 times the baseline value within 48 hours (AKIN criteria), or an increase &ge;1.5 times the baseline value within seven days (RIFLE criteria) (",
"      <a class=\"graphic graphic_table graphicRef83168 \" href=\"UTD.htm?10/4/10316\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"       \"Definition of acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rapidly progressive",
"      </strong>",
"      &mdash; Kidney disease that progresses for weeks.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic &mdash;",
"      </strong>",
"      A glomerular filtration rate less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 for three months or more",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of kidney damage such as albuminuria, urine sediment abnormalities, or findings on renal imaging or renal biopsy (",
"      <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link&amp;anchor=H27258481#H27258481\">",
"       \"Definition and staging of chronic kidney disease\", section on 'Definition of CKD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The assessment of disease duration is best performed by comparing the current serum creatinine concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinalysis with previous results. As an example, a patient with a current serum creatinine concentration of 4.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (354",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and a value of 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    one month previously has acute or rapidly progressive disease. In contrast, the same patient with a prior serum creatinine concentration of 3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    two years ago probably has slowly progressive chronic kidney disease but could have acute kidney injury superimposed upon stable chronic kidney disease.",
"   </p>",
"   <p>",
"    When a previous urinalysis, serum creatinine concentration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic study are unavailable, certain findings from the history and physical examination, may suggest the duration of disease. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recent onset of symptoms or signs, such as fever and discolored urine, suggests an acute process.",
"     </li>",
"     <li>",
"      Little or no urine output suggests an acute component, since prolonged oliguria (output less than 500",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      is associated with advanced renal failure.",
"     </li>",
"     <li>",
"      An increasing serum creatinine concentration after the initial evaluation is indicative of at least an acute or rapidly progressive component to the disease, while a stable value suggests chronic kidney disease. In addition, the rate of rise in the serum creatinine concentration may help distinguish among possible causes of acute kidney injury. As an example, the serum creatinine concentration tends to rise progressively and usually at a rate greater than 0.3 to 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (26 to 44",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      per day in acute tubular necrosis. In comparison, a slower rate of rise with periodic downward fluctuations (due to variations in renal perfusion) is suggestive of prerenal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H26745604#H26745604\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Distinction of prerenal disease from ATN'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiologic examination, most commonly by renal ultrasonography, showing small, echogenic kidneys is most consistent with a chronic disease because of the progressive loss of renal parenchyma and increased interstitial fibrosis over time. However, the presence of normal-sized kidneys does",
"      <strong>",
"       not",
"      </strong>",
"      exclude chronic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other findings are less helpful. As an example, most patients with chronic kidney disease develop anemia (due primarily to erythropoietin deficiency). However, a variety of acute diseases also can be associated with anemia due to hemolysis or bleeding. Similarly, although the absence of anemia in a patient with substantial renal insufficiency is more compatible with acute disease, some patients with chronic kidney disease are not anemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In-hospital acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who develop kidney injury in the hospital, the date of onset can be precisely timed if the serum creatinine concentration has been measured frequently as part of routine blood testing. Suppose, for example, that a patient has had a stable serum creatinine concentration, which then begins to rise progressively on day five. In such a patient, there must have been some insult on day four or a cumulative insult that has become clinically apparent (such as aminoglycoside therapy, a hypotensive episode, or administration of radiographic contrast media). Careful perusal of the patient's chart may identify the precipitating event on day four (eg, hypotension, radiocontrast exposure, or cessation of intravenous hydration in a patient treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link&amp;anchor=H101518418#H101518418\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Acyclovir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF KIDNEY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once kidney disease is discovered, the presence and degree of renal dysfunction is assessed and steps are taken to identify the cause. The history and physical examination are frequently helpful (eg, acute kidney injury developing after radiocontrast exposure or a course of aminoglycoside therapy). Initial testing must include an estimation of the glomerular filtration rate and examination of the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Estimation of glomerular filtration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the glomerular filtration rate (GFR) gives an approximate measure of the number of functioning nephrons. A reduction in GFR implies either progression of the underlying disease or the development of a superimposed and often reversible problem, such as decreased renal perfusion due to volume depletion. An increase in GFR, on the other hand, is indicative of improvement in kidney function, whereas a stable GFR implies stable disease.",
"   </p>",
"   <p>",
"    The most common methods utilized to estimate the GFR in adults are the serum creatinine concentration, the creatinine clearance, and estimation equations based upon the serum creatinine concentration and variables such as age, sex, and race. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H6#H6\">",
"     \"Assessment of kidney function\", section on 'Estimation of GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum creatinine and GFR estimation equations can only be used in patients with",
"    <strong>",
"     stable kidney function",
"    </strong>",
"    . With acute kidney injury, for example, the GFR is initially markedly reduced but there has not yet been time for creatinine to accumulate and for the serum creatinine concentration to reflect the degree of renal dysfunction.",
"   </p>",
"   <p>",
"    The estimation equations may be less accurate in some populations. These include individuals with a high, normal, or near-normal GFR, children, certain ethnic groups, pregnant women, and those with unusual muscle mass, body habitus, or weight (eg, morbid obesity or malnourished). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659825#H20659825\">",
"     \"Assessment of kidney function\", section on 'Limitations of estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most clinical settings (other than dose adjustment for certain medications), exact knowledge of the GFR is not required. As an example, knowing that the GFR is 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    rather than 30 or 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    provides little useful information to help determine therapy. What is important to know in the patient with kidney disease is whether the GFR (and therefore disease severity) is changing or is stable. This can usually be determined by monitoring changes in the serum creatinine or the estimated GFR in patients with a relatively constant body mass and diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     URINARY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis involves both use of a urine dipstick and microscopic examination of the urine sediment. The dipstick can test for protein, pH, glucose, hematuria, pyuria, and, with many dipsticks, specific gravity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4221132#H4221132\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine dipstick'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microscopic examination of the urine sediment is an essential component of the diagnostic evaluation, since characteristic findings strongly suggest certain diagnoses (",
"    <a class=\"graphic graphic_table graphicRef56160 \" href=\"UTD.htm?37/51/38715\">",
"     table 1",
"    </a>",
"    ). As an example, the presence of muddy brown granular casts and epithelial cell casts in a patient with acute kidney injury is highly suggestive of acute tubular necrosis (ATN). However, the absence of these urinary findings does not exclude the diagnosis and their presence does not always establish the diagnosis of ATN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H13#H13\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine sediment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H26746321#H26746321\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Urinalysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of one red cell cast is diagnostic of glomerular hematuria (glomerulonephritis or vasculitis), while significant proteinuria is generally indicative of some form of glomerular disease. Evaluation of red cell morphology may be helpful in patients with hematuria. The red cells are typically uniform (isomorphic) and round (",
"    <a class=\"graphic graphic_picture graphicRef80282 \" href=\"UTD.htm?43/46/44768\">",
"     picture 1",
"    </a>",
"    ), as in a peripheral blood smear, in non-glomerular disease, but usually have a dysmorphic appearance in glomerular disease (",
"    <a class=\"graphic graphic_picture graphicRef79440 \" href=\"UTD.htm?24/0/24591\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62064 \" href=\"UTD.htm?13/47/14079\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H17#H17\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who have glomerular disease, the urinalysis can help subclassify patients into those with glomerulonephritis and those with a nephrotic pattern in which moderate to heavy proteinuria and a generally bland urine sediment (",
"    <a class=\"graphic graphic_table graphicRef62131 \" href=\"UTD.htm?34/13/35036\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Clinical patterns of glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even a normal urinalysis has diagnostic utility. The finding of normal or near-normal urinalysis, characterized by few cells with few or no casts or proteinuria, suggests different disorders based upon disease duration (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H1067675#H1067675\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Normal or near-normal urinalysis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With an acute process, prerenal disease, urinary tract obstruction, hypercalcemia, cast nephropathy in multiple myeloma, some cases of acute tubular necrosis, vascular diseases that produce glomerular ischemia but not infarction (eg, scleroderma, atheroemboli, and polyarteritis nodosa), tumor lysis syndrome, and acute phosphate nephropathy.",
"     </li>",
"     <li>",
"      With chronic disease, prerenal disease due to heart failure or cirrhosis, hypertensive nephrosclerosis, urinary tract obstruction, and tubulointerstitial disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic evaluation of patients with isolated hematuria or proteinuria and a normal serum creatinine concentration are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urine sodium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine can be rendered virtually sodium-free (urine sodium concentration less than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and can be as low as 1",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in the presence of volume depletion and normal renal function. Thus, measurement of the urine sodium concentration is a standard part of the evaluation of patients who are thought to be volume depleted. The supportive data and when the urine sodium may be higher than expected (eg, diuretic therapy) in hypovolemic patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H780669#H780669\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Urine sodium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute kidney injury (AKI), measurement of the urine sodium concentration may be helpful in distinguishing acute tubular necrosis (ATN) from prerenal disease which, if severe, can cause ATN. The urine sodium concentration is usually above 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in ATN and below 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in prerenal disease. However, since the urinary sodium concentration is influenced by the urine volume, there is substantial overlap due in part to variations in the urine volume. As an example, a given rate of sodium excretion will be associated with a lower urine sodium concentration by dilution in patients who have a high urine output and with a higher urine sodium concentration if the urine output is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H513307564\">",
"    <span class=\"h4\">",
"     Fractional excretion of sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of variations in urine volume can be eliminated by calculating the fractional excretion of sodium (FENa), which is defined by the following equation that does not include the urine volume:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp; x &nbsp; SCr",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;FENa, percent &nbsp; &nbsp;= &nbsp; &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; &nbsp;x &nbsp; &nbsp;100",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SNa &nbsp; x &nbsp; UCr",
"   </p>",
"   <p>",
"    where UCr and SCr are the urine and serum creatinine concentrations, respectively, and UNa and SNa are the urine and serum sodium concentrations, respectively. Calculators for the FENa are available using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or SI units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The FENa is the most accurate screening test to differentiate between prerenal disease and ATN. A value below 1 percent suggests prerenal disease, where the reabsorption of almost all of the filtered sodium represents an appropriate response to decreased renal perfusion. In comparison, while a value above 2 percent usually indicates ATN, while a value between 1 and 2 percent can be seen with either disorder.",
"   </p>",
"   <p>",
"    The supporting data, including derivation of the FENa formula in which the urine volume terms cancel out, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H26746750#H26746750\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Fractional excretion of sodium and urine sodium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174480491\">",
"    <span class=\"h5\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several limitations to the use of FENa in distinguishing prerenal disease from ATN as the cause of AKI. This issue is discussed in detail elsewhere but a few examples will be provided here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H5#H5\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'Limitations of FENa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FENa may remain below 1 percent when ATN is superimposed upon a chronic prerenal disease, such as cirrhosis or heart failure, or in a minority of patients with nonoliguric postischemic (ischemic) ATN who may have persistent renal ischemia and less severe ATN.",
"     </li>",
"     <li>",
"      A low FENa is not unique to prerenal disease, since it can occur with other causes of AKI that are associated with a low GFR and relatively intact tubular function. These include acute glomerulonephritis, vasculitis, and contrast-induced nephropathy.",
"     </li>",
"     <li>",
"      Patients with AKI are often treated with diuretics which, if effective, can raise the FENa, even in patients with prerenal disease. Potential alternative in such patients, which have been less well studied than FENa, include the fractional excretion of molecules such as urea,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and uric acid that are primarily reabsorbed and, with uric acid, secreted in the proximal tubule, which is proximal to the sites of action of loop diuretics (loop of Henle) or thiazide diuretics (distal tubule).",
"     </li>",
"     <li>",
"      The FENa defining sodium retention",
"      <strong>",
"       varies with the filtered sodium load",
"      </strong>",
"      : below 1 percent when the filtered sodium load is low due to the marked reduction in glomerular filtration rate (GFR) in AKI; and progressively lower as the filtered sodium load increases, reaching a value of",
"      <strong>",
"       less than 0.1 percent",
"      </strong>",
"      when the GFR is normal. If, for example, the normal GFR is 180",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      (125",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and the normal plasma water sodium concentration is 150",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      then the daily filtered sodium load will be 27,000",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      In a patient with prerenal disease, urine sodium excretion can be reduced to less than 27",
"      <span class=\"nowrap\">",
"       meq/day,",
"      </span>",
"      which represents a FENa below 0.1 percent if a normal GFR is maintained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chronic kidney disease (CKD), the addition of a prerenal process may not result in a low urine sodium concentration or FENa since the renal tubules may be unable to maximally conserve water and sodium. In such patients, the prerenal state may be strongly suggested from the history (eg, vomiting, diarrhea, diuretic therapy) and physical examination (eg, relative hypotension, reduced skin turgor). A judicious trial of fluid repletion may result in recovery of renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the glomerular filtration rate (GFR) may be markedly reduced in patients with acute kidney injury (AKI), the urine volume (also called urine output) is variable, ranging from below normal (oliguria) to normal or even above normal levels. These findings are related to the fact that the urine volume is determined by the",
"    <strong>",
"     difference",
"    </strong>",
"    between the GFR and the rate of tubular reabsorption, not by the GFR alone. If, for example, a patient with advanced acute or chronic kidney disease has a GFR of 5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (normal 140 to 180",
"    <span class=\"nowrap\">",
"     L/day),",
"    </span>",
"    the daily urine output will be 1.5 L if only 3.5 L of the filtrate is reabsorbed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=see_link\">",
"     \"Urine output and residual renal function in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the urine volume is usually of little diagnostic value. However, little or no urine (anuria) is diagnostically useful in patients with AKI. Causes of this finding include shock, complete bilateral urinary tract obstruction, renal cortical necrosis, and bilateral vascular occlusion (as with a dissecting aneurysm or thrombotic thrombocytopenic purpura-hemolytic uremic syndrome). Decreased urine volume is common in acute tubular necrosis, but anuria is rare in acute tubular necrosis in the absence of shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=see_link\">",
"     \"Nonoliguric versus oliguric acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RADIOLOGIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of radiologic studies are used to evaluate the patient with kidney disease. These tests are performed alone or in combination for the detection, diagnosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evaluation of multiple conditions. They are principally required to assess urinary tract obstruction, kidney stones, renal cyst or mass, disorders with characteristic radiographic findings, renal vascular diseases, and, in children and young adults, vesicoureteral reflux.",
"   </p>",
"   <p>",
"    Because of safety, ease of use, and the information provided, the most commonly used radiographic technique in patients presenting with kidney disease is renal ultrasonography. Since obstruction is a readily reversible disorder,",
"    <strong>",
"     all",
"    </strong>",
"    patients presenting with acute or chronic kidney disease of unknown etiology should undergo ultrasonography, the modality of choice to assess possible obstructive disease. Helical CT scan is generally preferred with patients with flank pain and possible urolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=see_link\">",
"     \"Radiologic assessment of renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with moderate to advanced kidney disease (dialysis-dependent or estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided if possible. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ROLE OF RENAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is most commonly obtained when noninvasive evaluation has been unable to establish the correct diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/60/35785/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The major indications for renal biopsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated glomerular hematuria with proteinuria",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"     <li>",
"      Acute nephritic syndrome",
"     </li>",
"     <li>",
"      Unexplained acute or rapidly progressive kidney disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to renal biopsy, including indications, when biopsy may not be necessary, prebiopsy evaluation, technique, and complications, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       \"Patient information: Chronic kidney disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=see_link\">",
"       \"Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to the patient with acute, rapidly progressive or chronic kidney disease primarily involves establishing the correct diagnosis and estimating the degree of renal dysfunction. The causes of acute or chronic kidney disease are traditionally classified by that portion of the renal anatomy most affected by the disorder. These include prerenal, vascular, glomerular, tubulointerstitial, and obstructive disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Major causes of kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with renal disease may present in a variety of ways. These include signs and symptoms resulting directly from alterations in kidney function, asymptomatic elevations in the serum creatinine concentration or abnormalities on urinalysis, symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of renal dysfunction, systemic symptoms and findings,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      incidental findings on radiographic testing performed for some other reason. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Presenting manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once renal disease is discovered, the degree of renal dysfunction is assessed. The most common methods utilized to estimate the GFR in adults are the serum creatinine concentration, the creatinine clearance, and estimation equations based upon the serum creatinine concentration: the Cockcroft-Gault equation, Modification of Diet in Renal Disease (MDRD) study equation, and the CKD-EPI equation. Serum creatinine and GFR estimation equations can only be used in patients with",
"      <strong>",
"       stable kidney function",
"      </strong>",
"      . With acute kidney injury, the GFR is initially markedly reduced but there has not yet been time for creatinine to accumulate and for the serum creatinine concentration to reflect the degree of renal dysfunction. However, in most clinical settings (other than dose adjustment for medications), exact knowledge of the GFR is not required. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Estimation of glomerular filtration rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urinalysis is the most important noninvasive test in the diagnostic evaluation, since characteristic findings on microscopic examination of the urine sediment strongly suggest certain diagnoses. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Urinalysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute kidney injury, the fractional excretion of sodium (FENa) is the most accurate screening test to differentiate between prerenal disease and acute tubular necrosis (ATN). A value below 1 percent suggests prerenal disease; in comparison, a value between 1 and 2 percent may be seen with either disorder, while a value above 2 percent usually indicates ATN. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute kidney injury'",
"      </a>",
"      above.) By comparison, among patients with chronic kidney disease, the addition of a prerenal process may not result in a low urine sodium concentration or FENa. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important aspect of the initial evaluation is the determination of disease duration. Although the distinction between acute, rapidly progressive, and chronic kidney disease is arbitrary, the differential diagnosis can frequently be narrowed if the disease duration is known. This assessment is best performed by comparing the current urinalysis and plasma creatinine concentration with previous results, if available.",
"     </li>",
"     <li>",
"      Because of safety, ease of use, and the information provided, the most commonly used radiographic technique in patients presenting with renal disease is renal ultrasonography. Since obstruction is a readily reversible disorder,",
"      <strong>",
"       all",
"      </strong>",
"      patients presenting with acute or chronic renal failure of unknown etiology should undergo ultrasonography, the modality of choice to assess possible obstructive disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radiologic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A renal biopsy is most commonly obtained in patients with suspected glomerulonephritis or vasculitis and in those with otherwise unexplained acute or subacute renal failure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Role of renal biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987, p. 41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/2\">",
"      Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/3\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/4\">",
"      Lia&ntilde;o F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/5\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004; 66:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/6\">",
"      Prescott GJ, Metcalfe W, Baharani J, et al. A prospective national study of acute renal failure treated with RRT: incidence, aetiology and outcomes. Nephrol Dial Transplant 2007; 22:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/7\">",
"      Zhang L, Wang M, Wang H. Acute renal failure in chronic kidney disease--clinical and pathological analysis of 104 cases. Clin Nephrol 2005; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/8\">",
"      Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007; 49:A6.",
"     </a>",
"    </li>",
"    <li>",
"     MedlinePlus file://www.nlm.nih.gov/medlineplus/ency/article/000471.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/10\">",
"      Madaio MP. Renal biopsy. Kidney Int 1990; 38:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/60/35785/abstract/11\">",
"      Appel, GB. Renal biopsy: How effective, what technique, and how safe. J Nephrol 1993; 6:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7188 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35785=[""].join("\n");
var outline_f34_60_35785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428589108\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAJOR CAUSES OF KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prerenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tubular and interstitial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obstructive uropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Relative frequency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRESENTING MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Disease duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In-hospital acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ASSESSMENT OF KIDNEY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Estimation of glomerular filtration rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      URINARY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urine sodium excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H513307564\">",
"      Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H174480491\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Urine volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RADIOLOGIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ROLE OF RENAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7188|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/46/44768\" title=\"picture 1\">",
"      Phase contrast micrograph showing monomorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 2\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 3\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/51/38715\" title=\"table 1\">",
"      Urinary patterns associated with different kidney diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/13/35036\" title=\"table 2\">",
"      Differential glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/4/10316\" title=\"table 3\">",
"      Criteria for acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/62/22509\" title=\"table 4\">",
"      Definition and criteria for CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=related_link\">",
"      Chapter 8A: Effective circulating volume and the steady state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=related_link\">",
"      Nonoliguric versus oliguric acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=related_link\">",
"      Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=related_link\">",
"      Radiologic assessment of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28966?source=related_link\">",
"      Screening for chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=related_link\">",
"      Urine output and residual renal function in renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_60_35786="Spitz histo 2";
var content_f34_60_35786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Histologic features of Spitz nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large epithelioid and spindle cells with abundant eosinophilic glassy cytoplasm. The nuclei demonstrate uniformity and often possess a single centrally placed nucleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35786=[""].join("\n");
var outline_f34_60_35786=null;
var title_f34_60_35787="Risk of a 2nd preterm birth";
var content_f34_60_35787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of recurrent preterm birth (PTB) in a second pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of PTB in next pregnancy",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of PTB before 28 weeks gestation",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No prior PTB",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        0.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prior PTB",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        22",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prior PTB at 23-27 weeks",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prior PTB at 28-34 weeks",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prior PTB at 35-36 weeks",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35787=[""].join("\n");
var outline_f34_60_35787=null;
var title_f34_60_35788="Urodynamic test options";
var content_f34_60_35788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urodynamic test options",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of UI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic test options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Urge",
"       </td>",
"       <td>",
"        Unstable bladder or detrusor instability (DI)",
"       </td>",
"       <td>",
"        No neurologic deficit",
"       </td>",
"       <td>",
"        Simple or multichannel CMG with or without EMG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detrusor hyperreflexia (DH), detrusor sphincter",
"dyssynergia (DSD)",
"       </td>",
"       <td>",
"        With neurologic lesion such as stroke, supraspinal cord",
"lesion, multiple sclerosis",
"       </td>",
"       <td>",
"        Multichannel CMG with or without EMG; video-urodynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detrusor hyperactivity with impaired contractility",
"(DHIC)",
"       </td>",
"       <td>",
"        Elderly, usually also associated with obstructive or",
"stress symptoms",
"       </td>",
"       <td>",
"        Multichannel CMG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Stress",
"       </td>",
"       <td>",
"        Impaired urethral support (female)",
"       </td>",
"       <td>",
"        Damage to pelvic muscles, nerves, and/or endofascia",
"       </td>",
"       <td>",
"        <p>",
"         Provocative stress test (direct visualization)",
"        </p>",
"        <p>",
"         Simple or multichannel CMG (to exclude",
"DI)",
"        </p>",
"        <p>",
"         UPP or leak point pressure",
"        </p>",
"        <p>",
"         Videourodynamics",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrinsic sphincter deficiency (ISD)",
"       </td>",
"       <td>",
"        Postoperative (after prostatectomy or anti-incontinence",
"surgery), trauma, aging, radiation, congenital (epispadias)",
"       </td>",
"       <td>",
"        Same as above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurogenic sphincter deficiency",
"       </td>",
"       <td>",
"        Neurogenic, sacral, or infrasacral lesion (eg,",
"myelomeningocele)",
"       </td>",
"       <td>",
"        <p>",
"         Same as above plus",
"        </p>",
"        <p>",
"         EMG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Overflow",
"       </td>",
"       <td>",
"        Overflow from under-active or acontractile detrusor",
"       </td>",
"       <td>",
"        Neurogenic (low spinal cord lesion, neuropathy,",
"postradical pelvic surgery), idiopathic detrusor failure",
"       </td>",
"       <td>",
"        <p>",
"         Uroflowmetry",
"        </p>",
"        <p>",
"         Multichannel CMG and pressure flow with EMG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overflow from outlet obstruction",
"       </td>",
"       <td>",
"        <p>",
"         Male: prostate gland disease, urethral stricture",
"        </p>",
"        <p>",
"         Female: postoperative",
"        </p>",
"       </td>",
"       <td>",
"        Uroflow, multichannel CMG, and pressure flow study",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The urodynamic tests listed are not recommended for routine use but are options for patients who require further evaluation (see text).",
"     <br>",
"      CMG: cystometrogram; EMG: electromyogram; PVR: postvoid residual; UPP: urethral pressure profilometry.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Fantl, JA, Newman, DK, Colling, J, et al, AHCPR Publication No. 96-0682. Public Health Service, Agency for Health Care Policy and Research, Rockville, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35788=[""].join("\n");
var outline_f34_60_35788=null;
var title_f34_60_35789="Cocaine toxicity - Rapid overview";
var content_f34_60_35789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cocaine toxicity: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine is a stimulant (sympathomimetic) that increases energy and produces euphoria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine produces toxicity in virtually every organ system, principally via hemodynamic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine may produce toxicity in virtually any organ; few complaints (particularly focal complaints) can be dismissed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest pain, shortness of breath, headache, focal neurological symptoms, and extremity symptoms are particularly worrisome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vital signs: Hypertension and tachycardia almost universal; hyperthermia may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS: Agitation common; focal signs suggest cerebrovascular accident",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pupils: Mydriasis common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lungs: Decreased breath sounds after smoking crack suggest pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extremities: Decreased pulses suggest vascular catastrophe, such as aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        General laboratory screening for poisoned patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fingerstick glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrocardiogram (ECG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen and salicylate levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine pregnancy test in women of childbearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Urine toxicology testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confirms cocaine use in last several days but does",
"        <strong>",
"         not",
"        </strong>",
"        confirm acute toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Advanced testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Driven by clinical symptoms (eg, cardiac biomarkers for suspected myocardial infarction; computerized tomography for suspected thoracic aortic dissection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Airway management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Succinylcholine relatively contraindicated in rapid sequence intubation; consider rocuronium (1 mg/kg IV) or other nondepolarizing agent as alternative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Psychomotor agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer benzodiazepines (eg, diazepam 5 to 10 mg IV every 3 to 5 minutes until agitation controlled)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe or symptomatic hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer diazepam (5 mg IV) or lorazepam (1 mg IV); may repeat q 5 minutes until sedated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phentolamine (1 to 5 mg IV); repeat as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DO NOT ADMINISTER BETA-BLOCKERS, INCLUDING LABETALOL. Beta-blockade is contraindicated in acute cocaine toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cocaine-associated myocardial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain ECG (accuracy with cocaine-associated chest pain unclear; see text)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer diazepam (5 mg IV) or lorazepam (1 mg IV) for agitation or hypertension; may repeat as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin 325 mg PO (assuming aortic dissection not suspected)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitroglycerin 0.4 mg SL with or without continuous infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phentolamine 1 to 5 mg IV, repeat as necessary; hold for SBP &lt;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DO NOT ADMINISTER BETA-BLOCKERS, INCLUDING LABETALOL. Beta-blockade is contraindicated in acute cocaine toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        QRS widening on ECG (rare; suggests profound toxicity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer sodium bicarbonate, 1 to 2 mEq/kg IV push",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with uncomplicated cocaine toxicity (agitation and sympathomimetic toxicity but no evidence of end-organ damage) may be treated with benzodiazepines and observed until symptoms resolve, then discharged.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with cocaine-associated chest pain and a normal or unchanged electrocardiogram, in whom thoracic aortic dissection is not a concern, should be observed for 9 to 12 hours. If repeat cardiac biomarkers and a repeat electrocardiogram are normal, such patients may be discharged.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with any evidence of end-organ toxicity should be admitted.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35789=[""].join("\n");
var outline_f34_60_35789=null;
var title_f34_60_35790="Release Mirena IUD";
var content_f34_60_35790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Release Mirena IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 148px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The inserter is then advanced to the level of the fundus, as indicated by the position of the flange. The slider is then pulled back to a position closest to the provider; an audible \"click\" signals release of the strings from the inserter. The insertion tube is then removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Berlex. Copyright &copy; Berlex.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35790=[""].join("\n");
var outline_f34_60_35790=null;
var title_f34_60_35791="Urinary flow patterns";
var content_f34_60_35791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal and abnormal urinary flow patterns in the evaluation of bladder dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormal urine flow patterns can be helpful in identifying underlying causes of voiding dysfunction. A tower curve pattern may be seen in patients with an overactive bladder, a plateau curve in patients with bladder obstruction, a plateau or staccato curve in patients with dysfunctional voiding, and an interrupted curve in patients with an underactive bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_60_35791=[""].join("\n");
var outline_f34_60_35791=null;
